Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Original article

Page Path
HOME > Article category > Original article
521 Original article
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
Intest Res 2017;15(1):90-96.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.90
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Our physicians work to expand the possibilities to treat female patients with inflammatory bowel disease (IBD) who wish to become pregnant. Although many drugs, including 5-aminosalicylate (5-ASA), corticosteroids, immunomodulators, and biologics, are used safely during pregnancy, few reports have described the therapeutic regimen throughout pregnancy and the management of patients who relapse during pregnancy precisely. The aim of this study was to assess the management of patients with IBD during pregnancy.

Methods

We identified 19 patients (five with Crohn's disease and 14 with ulcerative colitis [UC]) who became pregnant with a total of 23 pregnancies between May 2005 and May 2015 by reviewing the medical records of Kyoto University Hospital. The following data were collected: the maternal variables, the IBD treatment type, the disease activity, the pregnancy outcome, and the mode of delivery.

Results

Among the 19 patients, 18 had become pregnant after being diagnosed with IBD, while one had developed UC newly after pregnancy. Throughout the gestation, all patients were treated with probiotics, 5-ASA, prednisolone, cytapheresis, or infliximab. The relapse rate during pregnancy was 21.7% (5/23 cases). The five patients who experienced a relapse were able to pursue their pregnancy after intensification of their treatments. There were no adverse fetal or neonatal problems, except in one case that required an emergency Caesarean section because of placental dysfunction and in which a very low-birth-weight infant was born preterm.

Conclusions

Our present data confirmed that even if the disease flares up during pregnancy, good pregnancy outcomes can be achieved with an optimal intensification of the patient's treatment.

Citations

Citations to this article as recorded by  
  • The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients
    Chen‐Wang Chang, Shu‐Chen Wei, Jen‐Wei Chou, Tien‐Yu Huang, Chia‐Jung Kuo, Wen‐Hung Hsu, Chen‐Shuan Chung, Tzu‐Chi Hsu, Wei‐Chen Lin, Ming‐Jen Chen, Horng‐Yuan Wang
    Advances in Digestive Medicine.2023; 10(4): 226.     CrossRef
  • Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
    N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
    Drugs.2020; 80(16): 1699.     CrossRef
  • 5,706 View
  • 79 Download
  • 2 Web of Science
  • 2 Crossref
Close layer
Analysis of the clinical indications for opiate use in inflammatory bowel disease
Youran Gao, Sundas Khan, Meredith Akerman, Keith Sultan
Intest Res 2017;15(1):83-89.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.83
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Opiate use for inflammatory bowel disease (IBD), particularly high-dose (HD) use, is associated with increased mortality. It's assumed that opiate use is directly related to IBD-related complaints, although this hasn't been well defined. Our goal was to determine the indications for opiate use as a first step in developing strategies to prevent or decrease opiate use.

Methods

A retrospective cohort was formed of adults who were diagnosed with IBD and for whom outpatient evaluations from 2009 to 2014 were documented. Opiate use was defined if opiates were prescribed for a minimum of 30 days over a 365-day period. Individual chart notes were then reviewed to determine the clinical indication(s) for low-dose (LD) and HD opiate use.

Results

After a search of the electronic records of 1,109,277 patients, 3,226 patients with IBD were found. One hundred four patients were identified as opiate users, including 65 patients with Crohn's and 39 with ulcerative colitis; a total of 134 indications were available for these patients. IBD-related complaints accounted for 49.25% of the opiate indications, with abdominal pain (23.13%) being the most common. Overall, opiate use for IBD-related complaints (81.40% vs. 50.82%; P=0.0014) and abdominal pain (44.19% vs. 19.67%; P=0.0071) was more common among HD than among LD.

Conclusions

Our findings show that most IBD patients using opiates, particularly HD users, used opiates for IBD-related complaints. Future research will need to determine the degree to which these complaints are related to disease activity and to formulate non-opiate pain management strategies for patients with both active and inactive IBD.

Citations

Citations to this article as recorded by  
  • Integrated Single-Cell Transcriptome Analysis Reveals Novel Insights into the Role of Opioid Signaling in the Pathophysiology of Inflammatory Bowel Disease
    Mudan Zhang, Zhuo Xie, Shenghong Zhang, Gaoshi Zhou
    Biomedicines.2025; 13(6): 1398.     CrossRef
  • Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study
    Waseem Ahmed, Wade Billing, Timothy E Stump, Thomas Strobel, Sashidhar Sagi, Monika Fischer, Mathew Bohm
    Inflammatory Bowel Diseases.2023; 29(9): 1355.     CrossRef
  • Opioid use and associated factors in 1676 patients with inflammatory bowel disease: a multicentre quality improvement project
    Samantha Baillie, Jimmy K Limdi, Ash Bassi, Aileen Fraser, Gareth Parkes, Glyn Scott, Tim Raine, Christopher A Lamb, Nicholas A Kennedy, Natalia Fumis, Melissa A Smith, Andrew Nicolaou, Holly Emms, John Wye, Anouk Lehmann, Isabel Carbery, James Goodhand,
    Frontline Gastroenterology.2023; 14(6): 497.     CrossRef
  • Abdominal pain in quiescent inflammatory bowel disease
    Matthew D. Coates, Ansh Johri, Venkata Subhash Gorrepati, Parth Maheshwari, Shannon Dalessio, Vonn Walter, August Stuart, Walter Koltun, Nana Bernasko, Andrew Tinsley, Emmanuelle D. Williams, Kofi Clarke
    International Journal of Colorectal Disease.2021; 36(1): 93.     CrossRef
  • High-Dose Opioid Use Among Veterans with Unexplained Gastrointestinal Symptoms Versus Structural Gastrointestinal Diagnoses
    Salva N. Balbale, Lishan Cao, Itishree Trivedi, Jonah J. Stulberg, Katie J. Suda, Walid F. Gellad, Charlesnika T. Evans, Bruce L. Lambert, Neil Jordan, Laurie A. Keefer
    Digestive Diseases and Sciences.2021; 66(11): 3938.     CrossRef
  • Opioid Use Among Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
    Blake Niccum, Oluwatoba Moninuola, Kaia Miller, Hamed Khalili
    Clinical Gastroenterology and Hepatology.2021; 19(5): 895.     CrossRef
  • Pain in Inflammatory Bowel Disease Is Not Improved During Hospitalization: The Impact of Opioids on Pain and Healthcare Utilization
    Sameer K. Berry, Will Takakura, Catherine Bresee, Gil Y. Melmed
    Digestive Diseases and Sciences.2020; 65(6): 1777.     CrossRef
  • Predictors of mortality in inflammatory bowel disease patients treated for pneumonia
    Offir Ukashi, Yifatch Barash, Michael J. Segel, Bella Ungar, Shelly Soffer, Shomron Ben-Horin, Eyal Klang, Uri Kopylov
    Therapeutic Advances in Gastroenterology.2020;[Epub]     CrossRef
  • Integrated Psychological Care is Needed, Welcomed and Effective in Ambulatory Inflammatory Bowel Disease Management: Evaluation of a New Initiative
    Taryn Lores, Charlotte Goess, Antonina Mikocka-Walus, Kathryn L Collins, Anne L J Burke, Anna Chur-Hansen, Paul Delfabbro, Jane M Andrews
    Journal of Crohn's and Colitis.2019; 13(7): 819.     CrossRef
  • 6,324 View
  • 49 Download
  • 9 Web of Science
  • 9 Crossref
Close layer
15-Hydroxyprostaglandin dehydrogenase as a marker in colon carcinogenesis: analysis of the prostaglandin pathway in human colonic tissue
Dong-Hoon Yang, Yeon-Mi Ryu, Sun-Mi Lee, Jin-Yong Jeong, Soon Man Yoon, Byong Duk Ye, Jeong-Sik Byeon, Suk-Kyun Yang, Seung-Jae Myung
Intest Res 2017;15(1):75-82.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.75
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Cyclooxygenase-2 (COX-2), 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and microsomal prostaglandin E synthase-1 (mPGEs-1) regulate prostaglandin E2 (PGE2) expression and are involved in colon carcinogenesis. We investigated the expression of PGE2 and its regulating genes in sporadic human colon tumors and matched normal tissues.

Methods

Twenty colonic adenomas and 27 colonic adenocarcinomas were evaluated. COX-2 and 15-PGDH expression was quantified by real-time polymerase chain reaction. The expression of PGE2 and mPGEs-1 was measured using enzyme-linked immunosorbent assay and Western blotting, respectively.

Results

The expression of COX-2, mPGEs-1, and PGE2 did not differ between the adenomas and matched distant normal tissues. 15-PGDH expression was lower in adenomas than in the matched normal colonic tissues (P<0.001). In adenocarcinomas, mPGEs-1 and PGE2 expression was significantly higher (P<0.001 and P=0.020, respectively), and COX-2 expression did not differ from that in normal tissues (P=0.207). 15-PGDH expression was significantly lower in the normal colonic mucosa from adenocarcinoma patients than in the normal mucosa from adenoma patients (P=0.018).

Conclusions

Early inactivation of 15-PGDH, followed by activation of COX-2 and mPGEs-1, contributes to PGE2 production, leading to colon carcinogenesis. 15-PGDH might be a novel candidate marker for early detection of field defects in colon carcinogenesis.

Citations

Citations to this article as recorded by  
  • Plant-derived extracts or compounds for Helicobacter-associated gastritis: a systematic review of their anti-Helicobacter activity and anti-inflammatory effect in animal experiments
    Danni Chen, Wenlai Wang, Xiangyun Chen, Ning Liang, Jiawang Li, Wei Ding, Hongrui Zhang, Zhen Yang, Hongxia Zhao, Zhenhong Liu
    Chinese Medicine.2025;[Epub]     CrossRef
  • Targeting cyclooxygenase-2 for chemoprevention of inflammation-associated intestinal carcinogenesis: An update
    Kyung-Soo Chun, Eun-Hee Kim, Do-Hee Kim, Na-Young Song, Wonki Kim, Hye-Kyung Na, Young-Joon Surh
    Biochemical Pharmacology.2024; 228: 116259.     CrossRef
  • Dietary intake of walnut prevented Helicobacter pylori-associated gastric cancer through rejuvenation of chronic atrophic gastritis
    Jong Min Park, Young Min Han, Yong Jin Park, Ki Baik Hahm
    Journal of Clinical Biochemistry and Nutrition.2021; 68(1): 37.     CrossRef
  • Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials
    Nagendra S. Yarla, Venkateshwar Madka, Gopal Pathuri, Chinthalapally V. Rao
    International Journal of Molecular Sciences.2020; 21(24): 9609.     CrossRef
  • A glance at…antioxidant and antiinflammatory properties of dietary cobalt
    Michael J. Glade, Michael M. Meguid
    Nutrition.2018; 46: 62.     CrossRef
  • The prostanoid pathway contains potential prognostic markers for glioblastoma
    Alexandros Theodoros Panagopoulos, Renata Nascimento Gomes, Fernando Gonçalves Almeida, Felipe da Costa Souza, José Carlos Esteves Veiga, Anna Nicolaou, Alison Colquhoun
    Prostaglandins & Other Lipid Mediators.2018; 137: 52.     CrossRef
  • 6,095 View
  • 54 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients
Shinta Mizuno, Kosaku Nanki, Katsuyoshi Matsuoka, Keiichiro Saigusa, Keiko Ono, Mari Arai, Shinya Sugimoto, Hiroki Kiyohara, Moeko Nakashima, Kozue Takeshita, Makoto Naganuma, Wataru Suda, Masahira Hattori, Takanori Kanai
Intest Res 2017;15(1):68-74.   Published online January 31, 2017
DOI: https://doi.org/10.5217/ir.2017.15.1.68
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC) is proposed as a potential approach to resolving their dysbiosis; however, its safety and efficacy have not been confirmed. This single-arm, open-label, non-randomized study aimed to evaluate the safety and efficacy of FMT for Japanese patients with UC as the first registered clinical trial in Japan.

Methods

We enrolled 10 patients with active UC despite medical therapy. The donors were the patients' relatives and were carefully screened for infectious diseases. Fecal material was administered via colonoscopy, and the primary endpoint was the presence or absence of serious adverse events related to FMT. The secondary endpoint was a change in partial Mayo score at 12 weeks post-FMT. Scores ≤2 were considered a clinical response. Fecal samples were collected to follow changes in gut microbiota, while extracted complementary DNA were analyzed by a next-generation sequencer. We obtained written informed consent from all patients and donors. This study was approved by our Institutional Review Board and is registered in the University hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN 000012814).

Results

Five patients with moderate disease and five with severe disease were enrolled. No severe adverse effects were observed. One patient achieved clinical response; however, none of the patients' microbiota diversity recovered to the donor levels.

Conclusions

The use of single FMT for UC was safe; however, we failed to show its clinical efficacy and potential to change the intestinal microbiota.

Citations

Citations to this article as recorded by  
  • Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: A Systematic Review and Meta-analysis
    Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
    Clinical and Translational Gastroenterology.2023; 14(5): e00568.     CrossRef
  • Recipient-independent, high-accuracy FMT-response prediction and optimization in mice and humans
    Oshrit Shtossel, Sondra Turjeman, Alona Riumin, Michael R. Goldberg, Arnon Elizur, Yarin Bekor, Hadar Mor, Omry Koren, Yoram Louzoun
    Microbiome.2023;[Epub]     CrossRef
  • Transfer of FRozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial
    Andreas Stallmach, Philip Grunert, Johannes Stallhofer, Bettina Löffler, Michael Baier, Jürgen Rödel, Michael Kiehntopf, Sophie Neugebauer, Dietmar H. Pieper, Howard Junca, Andrea Tannapfel, Ute Merkel, Ulrike Schumacher, Maria Breternitz-Gruhne, Tabitha
    Trials.2022;[Epub]     CrossRef
  • An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
    Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
    Medicine.2022; 101(30): e29790.     CrossRef
  • Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
    Xiaochen Zhang, Dai Ishikawa, Toshifumi Ohkusa, Shinji Fukuda, Akihito Nagahara
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • The Effects of Multi-Donor Fecal Microbiota Transplantation Capsules Combined with Thalidomide on Hormone-Dependent Ulcerative Colitis
    Xiao-He Guo, Yan-Li Zhu, Lu Yang, Wen-Jing Li, Xue-Fang Du
    Infection and Drug Resistance.2022; Volume 15: 7495.     CrossRef
  • Fecal microbiota transplantation for ulcerative colitis
    Katsuyoshi Matsuoka
    Immunological Medicine.2021; 44(1): 30.     CrossRef
  • Bacteriotherapy for inflammatory bowel disease
    Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai
    Inflammation and Regeneration.2021;[Epub]     CrossRef
  • Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
    Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
    Journal of Clinical Medicine.2021; 10(5): 959.     CrossRef
  • Current status, complications and prospects of fecal microbiota transplantation therapy
    Ohara Tadashi
    Archives of Pathology and Clinical Research.2021; 5(1): 004.     CrossRef
  • Fecal Microbial Transplantation in Critically Ill Patients—Structured Review and Perspectives
    Ivana Cibulková, Veronika Řehořová, Jan Hajer, František Duška
    Biomolecules.2021; 11(10): 1459.     CrossRef
  • Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation
    Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. DuPont, Netanya S. Utay
    Digestive Diseases and Sciences.2020; 65(3): 741.     CrossRef
  • Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
    Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
    Journal of Digestive Diseases.2020; 21(3): 147.     CrossRef
  • Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
    Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
    PLOS ONE.2020; 15(9): e0238910.     CrossRef
  • Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
    Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
    Crohn's & Colitis 360.2020;[Epub]     CrossRef
  • Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
    Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
    Journal of Digestive Diseases.2020; 21(10): 534.     CrossRef
  • Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
    Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
    Journal of Gastrointestinal Infections.2020; 10(1): 16.     CrossRef
  • Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of steroid-dependent ulcerative colitis
    Young-Seok Cho
    Intestinal Research.2019; 17(1): 6.     CrossRef
  • RecurrentClostridium difficileInfection: Risk Factors, Treatment, and Prevention
    Jung Hoon Song, You Sun Kim
    Gut and Liver.2019; 13(1): 16.     CrossRef
  • 1) Microbiota and Gastrointestinal Diseases
    Takanori Kanai
    Nihon Naika Gakkai Zasshi.2019; 108(3): 401.     CrossRef
  • Fecal microbial transplantation
    Sonia Bouri, Ailsa Hart
    Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(5): 405.     CrossRef
  • The Value of Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Patients: A Systematic Review and Meta-Analysis
    Yantian Cao, Bangjie Zhang, Yuanyuan Wu, Qingzhi Wang, Jie Wang, Fangfang Shen
    Gastroenterology Research and Practice.2018; 2018: 1.     CrossRef
  • Gut microbiota‐immune‐brain interactions in chemotherapy‐associated behavioral comorbidities
    Kelley R. Jordan, Brett R. Loman, Michael T. Bailey, Leah M. Pyter
    Cancer.2018; 124(20): 3990.     CrossRef
  • Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation
    Seong Ran Jeon, Jocelyn Chai, Christiana Kim, Christine H. Lee
    Current Infectious Disease Reports.2018;[Epub]     CrossRef
  • Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?
    Chang Soo Eun
    Intestinal Research.2017; 15(2): 145.     CrossRef
  • Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome
    Shinta Mizuno, Tatsuhiro Masaoka, Makoto Naganuma, Taishiro Kishimoto, Momoko Kitazawa, Shunya Kurokawa, Moeko Nakashima, Kozue Takeshita, Wataru Suda, Masaru Mimura, Masahira Hattori, Takanori Kanai
    Digestion.2017; 96(1): 29.     CrossRef
  • Intestinal immune response is regulated by gut microbe
    Shun TANEMOTO, Tomohisa SUJINO, Takanori KANAI
    Japanese Journal of Clinical Immunology.2017; 40(6): 408.     CrossRef
  • 8,511 View
  • 98 Download
  • 26 Web of Science
  • 27 Crossref
Close layer
The submucosal fibrosis: what does it mean for colorectal endoscopic submucosal dissection?
Eun Kyoung Kim, Dong Soo Han, Youngouk Ro, Chang Soo Eun, Kyo-Sang Yoo, Young-Ha Oh
Intest Res 2016;14(4):358-364.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.358
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

Endoscopic submucosal dissection (ESD) allows removal of colorectal epithelial neoplasms en bloc regardless of size. Colorectal ESD is a difficult procedure because of technical difficulties and risks of complications. This study aimed to assess the relationship between ESD outcome and degree of submucosal fibrosis.

Methods

Patients with colorectal tumors undergoing ESD and their medical records were reviewed retrospectively. The degree of submucosal fibrosis was classified into three types. The relationship between ESD outcome and degree of submucosal fibrosis was analyzed.

Results

ESD was performed in 158 patients. Thirty-eight cases of F0 (no) fibrosis (24.1%) and 46 cases of F2 (severe) fibrosis (29.1%) were observed. Complete resection was achieved for 138 lesions (87.3%). Multivariate analysis demonstrated that submucosal invasion of tumor and histology of carcinoma were independent risk factors for F2 fibrosis. Severe fibrosis was an independent risk factor for incomplete resection.

Conclusions

Severe fibrosis is an important factor related to incomplete resection during colorectal ESD. In cases of severe fibrosis, the rate of complete resection was low even when ESD was performed by an experienced operator. Evaluation of submucosal fibrosis may be helpful to predict the submucosal invasion of tumors and technical difficulties in ESD.

Citations

Citations to this article as recorded by  
  • Learning curve of colorectal endoscopic submucosal dissection of an endoscopist experienced hands‐on training in Japan
    Sukit Pattarajierapan, Yutaka Saito, Hiroyuki Takamaru, Naoya Toyoshima, Naruemon Wisedopas, Natcha Wanpiyarat, Nathawadee Lerttanatum, Supakij Khomvilai
    Journal of Gastroenterology and Hepatology.2025; 40(1): 226.     CrossRef
  • Feasibility, safety and efficacy of endoscopic submucosal dissection for recurrent superficial rectal neoplastic lesions after transanal microsurgery
    Ali Jaafar, Jeremie Jacques, Sarah Leblanc, Romain Legros, Vincent Lepilliez, Arthur Berger, Edouard Chabrun, Yann Le Baleur, Mathieu Pioche, Maximilien Barret, Timothee Wallenhorst, Thibault Degand, Felix Corre, Marion Schaefer, Xavier Dray
    Digestive and Liver Disease.2025; 57(1): 68.     CrossRef
  • Risk Factors for Perforation in Endoscopic Treatment for Early Colorectal Cancer: A Nationwide ENTER-K Study
    Ik Hyun Jo, Hyun Gun Kim, Young-Seok Cho, Hyun Jung Lee, Eun Ran Kim, Yoo Jin Lee, Sung Wook Hwang, Kyeong-Ok Kim, Jun Lee, Hyuk Soon Choi, Yunho Jung, Chang Mo Moon
    Gut and Liver.2025; 19(1): 95.     CrossRef
  • Outcomes of Colonic Endoscopic Submucosal Dissection and Advanced Tissue Resection in Obese Patients: An Analysis of a Large Western Cohort
    Tara Keihanian, Mai Khalaf, Fares Ayoub, Elaheh Keivani Boroujeni, Salmaan A. Jawaid, Mohamed O. Othman
    Digestive Diseases and Sciences.2025; 70(6): 2117.     CrossRef
  • Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial
    Chang Kyo Oh, Young Wook Cho, Young-Seok Cho
    American Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Delays in definitive endoscopic resection of previously manipulated colorectal polyps as a risk factor for inferior resection outcomes
    Fares Ayoub, Grace E. Kim, Wenfei Wang, Dennis Chen, Uzma D. Siddiqui
    Gastrointestinal Endoscopy.2024; 100(1): 109.     CrossRef
  • Is there a best choice of equipment for colorectal endoscopic submucosal dissection?
    Francesco Cocomazzi, Sonia Carparelli, Nunzia Labarile, Antonio Capogreco, Marco Gentile, Roberta Maselli, Jahnvi Dhar, Jayanta Samanta, Alessandro Repici, Cesare Hassan, Francesco Perri, Antonio Facciorusso
    Expert Review of Medical Devices.2024; 21(7): 561.     CrossRef
  • Risk Factors for Post-Endoscopic Submucosal Dissection Electrocoagulation Syndrome in Patients with Colorectal Neoplasms: A Multicenter, Large-Scale, Retrospective Cohort Study by the Honam Association for the Study of Intestinal Disease (HASID)
    Hyo-Yeop Song, Seong-Jung Kim, Jun Lee, Byung Chul Jin, Dong Hyun Kim, Hyun-Soo Kim, Hyung-Hoon Oh, Young-Eun Joo, Dae-Seong Myung, Sang-Wook Kim, Geom-Seog Seo
    Journal of Clinical Medicine.2024; 13(13): 3932.     CrossRef
  • Hybrid Versus Conventional Colorectal Endoscopic Submucosal Dissection: A Multicenter Randomized Controlled Trial (Short-Endoscopic Submucosal Dissection)
    Dennis Yang, Muhammad K. Hasan, Salmaan Jawaid, Gurdeep Singh, Yasi Xiao, Mai Khalaf, Yutaka Tomizawa, Neil S. Sharma, Peter V. Draganov, Mohamed O. Othman
    American Journal of Gastroenterology.2024; 119(12): 2436.     CrossRef
  • The Derivation and External Validation of a Fibrosis Risk Model for Colorectal Tumours Undergoing Endoscopic Submucosal Dissection
    Sandro Sferrazza, Marcello Maida, Giulio Calabrese, Antonio Facciorusso, Lorenzo Fuccio, Leonardo Frazzoni, Roberta Maselli, Alessandro Repici, Roberto Di Mitri, João Santos-Antunes
    Journal of Clinical Medicine.2024; 13(15): 4517.     CrossRef
  • Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center
    Yunqing Zeng, Jinhou Li, Yuan Zheng, Di Zhang, Ning Zhong, Xiuli Zuo, Yanqing Li, Wenbin Yu, Jiaoyang Lu
    Annals of Medicine.2024;[Epub]     CrossRef
  • Comparing underwater endoscopic submucosal dissection and conventional endoscopic submucosal dissection for large laterally spreading tumor: a randomized controlled trial (with video)
    Chang Kyo Oh, Hwe Hoon Chung, Jae Keun Park, Jiyoon Jung, Hee Yeon Lee, Yu Jin Kim, Jin Bae Kim
    Gastrointestinal Endoscopy.2024; 100(6): 1079.     CrossRef
  • Outcomes and Learning Curve in Endoscopic Submucosal Dissection of Rectal Neoplasms with Severe Fibrosis: Experience of a Western Center
    Catarina Félix, Pedro Barreiro, Rui Mendo, André Mascarenhas, Cristina Chagas
    GE - Portuguese Journal of Gastroenterology.2023; 30(3): 221.     CrossRef
  • Endoscopic submucosal dissection for colorectal polyps: outcome determining factors
    Chi Woo Samuel Chow, Tak Lit Derek Fung, Pak Tat Chan, Kam Hung Kwok
    Surgical Endoscopy.2023; 37(2): 1293.     CrossRef
  • Safety and feasibility of same-day discharge after endoscopic submucosal dissection: a Western multicenter prospective cohort study
    William King, Peter Draganov, V.Subhash Gorrepati, Maham Hayat, Hiroyuki Aihara, Michael Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Dennis Yang
    Gastrointestinal Endoscopy.2023; 97(6): 1045.     CrossRef
  • Is colorectal endoscopic submucosal dissection safe and effective for 15–19-mm tumors?
    Yunho Jung, Young Hwangbo, Young Sin Cho, Seong Woo Choi, Seong Ran Jeon, Hyun Gun Kim, Bong Min Ko, Jin-O Kim
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • Initial multicenter experience using a novel articulating through-the-scope traction device for endoscopic submucosal dissection
    Maham Hayat, Alexander Schlachterman, Grace Schiavone, Meir Mizrahi, Jong Kyu Park, Vivek Kumbhari, Antonio Cheesman, Peter V Draganov, Muhammad Khalid Hasan, Dennis Yang
    Endoscopy International Open.2023; 11(08): E778.     CrossRef
  • Novel beagle model of gastric local fibrotic target lesions for the evaluation and training of endoscopic techniques
    Xiao-Jian He, Xiao-Ling Wang, Chuan-Shen Jiang, Dong-Gui Hong, Hai-Lan Lin, Yun-Ping Zheng, Han Li, Xin-Jiang Chen, Jian-Xiao Huang, Ling-Shuang Dai, Mei-Yan Liu, Bao-Xiang Luo, Dong-Liang Li, Da-Zhou Li, Wen Wang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Comparison of precutting endoscopic mucosal resection and endoscopic submucosal dissection for large (20–30 mm) flat colorectal lesions
    Chang Kyo Oh, Young Wook Cho, In Hyoung Choi, Han Hee Lee, Chul‐Hyun Lim, Jin Su Kim, Bo‐In Lee, Young‐Seok Cho
    Journal of Gastroenterology and Hepatology.2022; 37(3): 568.     CrossRef
  • Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study
    Peter V. Draganov, Hiroyuki Aihara, Michael S. Karasik, Saowanee Ngamruengphong, Abdul Aziz Aadam, Mohamed O. Othman, Neil Sharma, Ian S. Grimm, Alaa Rostom, B. Joseph Elmunzer, Salmaan A. Jawaid, Donevan Westerveld, Yaseen B. Perbtani, Brenda J. Hoffman,
    Gastroenterology.2021; 160(7): 2317.     CrossRef
  • Pocket-creation method improves efficacy of colorectal endoscopic submucosal dissection: a system review and meta-analysis
    Jian Gong, Tong Chen, Yuyong Tan, Deliang Liu
    European Journal of Gastroenterology & Hepatology.2021; 33(10): 1241.     CrossRef
  • Impact of Procedure Time of Preceding Endoscopic Submucosal Dissection on the Difficulty of Laparoscopic Rectal Surgery
    Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Shigenobu Emoto, Koji Murono, Hirofumi Sonoda, Hiroaki Ishii, Soichiro Ishihara
    International Surgery.2021; 105(1-3): 528.     CrossRef
  • Factors Associated with Fibrosis during Colorectal Endoscopic Submucosal Dissection: Does Pretreatment Biopsy Potentially Elicit Submucosal Fibrosis and Affect Endoscopic Submucosal Dissection Outcomes?
    Masatake Kuroha, Hisashi Shiga, Yoshitake Kanazawa, Hiroshi Nagai, Tomoyuki Handa, Ryo Ichikawa, Motoyuki Onodera, Takeo Naito, Rintaro Moroi, Tomoya Kimura, Katsuya Endo, Yoichi Kakuta, Yoshitaka Kinouchi, Tooru Shimosegawa, Atsushi Masamune
    Digestion.2021; 102(4): 590.     CrossRef
  • Endoscopic submucosal dissection in rectal tumors extending or not to the dentate line: A comparative analysis
    Déborah Roland, Gabriel Rahmi, Enrique Pérez-Cuadrado-Robles, Guillaume Perrod, Jérémie Jacques, Maximilien Barret, Sarah Leblanc, Arthur Berger, Jérémie Albouys, Stanislas Chaussade, Christophe Cellier
    Digestive and Liver Disease.2020; 52(3): 296.     CrossRef
  • Novel approach to endoscopic submucosal dissection of a cecal lesion with nonlifting sign by submucosal fatty tissue with use of selective-regulation high-pressure water-jet method and immersion in saline solution
    Felipe Ramos-Zabala, Sabina Beg, Marian García-Mayor, Adolfo Parra-Blanco, Luis Moreno-Almazán
    VideoGIE.2020; 5(3): 116.     CrossRef
  • Review on colorectal endoscopic submucosal dissection focusing on the technical aspect
    Tak Lit Derek Fung, Chi Woo Samuel Chow, Pak Tat Chan, Kam Hung Kwok
    Surgical Endoscopy.2020; 34(9): 3766.     CrossRef
  • Endoscopic Biopsy in Differential Diagnosis of Colorectal Serrated Lesions
    K. D. Khalin, M. Yu. Agapov, L. V. Zvereva, K. V. Stegniy
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2020; 30(3): 42.     CrossRef
  • Predictors for Submucosal Fibrosis in Patients With Superficial Squamous Esophageal Neoplasia Undergoing Endoscopic Submucosal Dissection
    Xiaoduan Zhuang, Ming Xu, Zhenyu Chen, Jianqi Wang, Kai Qian, Shihao Wang, Guoming Deng, Yang Bai
    Clinical and Translational Gastroenterology.2020; 11(8): e00188.     CrossRef
  • Hybrid resection with ESD and FTRD: Could this be a rescue treatment in the presence of severe submucosal fibrosis?
    Gianluca Andrisani, Francesco Maria Di Matteo
    Digestive and Liver Disease.2019; 51(4): 607.     CrossRef
  • Factors Predictive of Complete Excision of Large Colorectal Neoplasia Using Hybrid Endoscopic Submucosal Dissection: A KASID Multicenter Study
    Yunho Jung, Jong Wook Kim, Jeong-Sik Byeon, Hoon Sup Koo, Sun-Jin Boo, Jun Lee, Young Hwangbo, Yoon Mi Jeen, Hyun Gun Kim
    Digestive Diseases and Sciences.2018; 63(10): 2773.     CrossRef
  • Perforation and Postoperative Bleeding Associated with Endoscopic Submucosal Dissection in Colorectal Tumors: An Analysis of 398 Lesions Treated in Saga, Japan
    Koji Yamamoto, Ryo Shimoda, Shinichi Ogata, Megumi Hara, Yoichiro Ito, Naoyuki Tominaga, Atsushi Nakayama, Yasuhisa Sakata, Nanae Tsuruoka, Ryuichi Iwakiri, Kazuma Fujimoto
    Internal Medicine.2018; 57(15): 2115.     CrossRef
  • The efficacy of the pocket-creation method for cases with severe fibrosis in colorectal endoscopic submucosal dissection
    Naohisa Yoshida, Yuji Naito, Ritsu Yasuda, Takaaki Murakami, Ryohei Hirose, Kiyoshi Ogiso, Yutaka Inada, Hideyuki Konishi, Rafiz Abdul Rani, Mitsuo Kishimoto, Eiichi Konishi, Masayoshi Nakanishi, Yoshito Itoh
    Endoscopy International Open.2018; 06(08): E975.     CrossRef
  • Local recurrence and subsequent endoscopic treatment after endoscopic piecemeal mucosal resection with or without precutting in the colorectum
    Myeongsook Seo, Eun Mi Song, Gwang Un Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
    Intestinal Research.2017; 15(4): 502.     CrossRef
  • 6,270 View
  • 60 Download
  • 36 Web of Science
  • 33 Crossref
Close layer
A wide variation of the quality of colonoscopy reporting system in the real clinical practice in southeastern area of Korea
Jung Min Lee, Yu Jin Kang, Eun Soo Kim, Yoo Jin Lee, Kyung Sik Park, Kwang Bum Cho, Seong Woo Jeon, Min Kyu Jung, Hyun Seok Lee, Eun Young Kim, Jin Tae Jung, Byung Ik Jang, Kyeong Ok Kim, Yun Jin Chung, Chang Hun Yang
Intest Res 2016;14(4):351-357.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.351
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

Establishment of a colonoscopy reporting system is a prerequisite to determining and improving quality. This study aimed to investigate colonoscopists' opinions and the actual situation of a colonoscopy reporting system in a clinical practice in southeastern area of Korea and to assess the factors predictive of an inadequate reporting system.

Methods

Physicians who performed colonoscopies in the Daegu-Gyeongbuk province of Korea and were registered with the Korean Society of Gastrointestinal Endoscopy (KSGE) were interviewed via mail about colonoscopy reporting systems using a standardized questionnaire.

Results

Of 181 endoscopists invited to participate, 125 responded to the questionnaires (response rate, 69%). Most responders were internists (105/125, 84%) and worked in primary clinics (88/125, 70.4%). Seventy-one specialists (56.8%) held board certifications for endoscopy from the KSGE. A median of 20 colonoscopies (interquartile range, 10–47) was performed per month. Although 88.8% of responders agreed that a colonoscopy reporting system is necessary, only 18.4% (23/125) had achieved the optimal reporting system level recommended by the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. One-third of endoscopists replied that they did not use a reporting document for the main reasons of "too busy" and "inconvenience." Non-endoscopy specialists and primary care centers were independent predictive factors for failure to use a colonoscopy reporting system.

Conclusions

The quality of colonoscopy reporting systems varies widely and is considerably suboptimal in actual clinical practice settings in southeastern Korea, indicating considerable room for quality improvements in this field.

Citations

Citations to this article as recorded by  
  • Association of Poor Differentiation or Positive Vertical Margin with Residual Disease in Patients with Subsequent Colectomy after Complete Macroscopic Endoscopic Resection of Early Colorectal Cancer
    Ki Ju Kim, Hyun Seok Lee, Seong Woo Jeon, Sun Jin, Sang Won Lee
    Gastroenterology Research and Practice.2017; 2017: 1.     CrossRef
  • Derivation and validation of a risk scoring model to predict advanced colorectal neoplasm in adults of all ages
    Hyo‐Joon Yang, Sungkyoung Choi, Soo‐Kyung Park, Yoon Suk Jung, Kyu Yong Choi, Taesung Park, Ji Yeon Kim, Dong Il Park
    Journal of Gastroenterology and Hepatology.2017; 32(7): 1328.     CrossRef
  • Screening strategy for colorectal cancer according to risk
    Dong Soo Han
    Journal of the Korean Medical Association.2017; 60(11): 893.     CrossRef
  • 7,381 View
  • 36 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Symptomatic improvement with gluten restriction in irritable bowel syndrome: a prospective, randomized, double blinded placebo controlled trial
Vinay G Zanwar, Sunil V Pawar, Pravir A Gambhire, Samit S Jain, Ravindra G Surude, Vinaya B Shah, Qais Q Contractor, Pravin M Rathi
Intest Res 2016;14(4):343-350.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.343
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

The existence of non-celiac gluten sensitivity has been debated. Indeed, the intestinal and extra-intestinal symptoms of many patients with irritable bowel syndrome (IBS) but without celiac disease or wheat allergy have been shown to improve on a gluten-free diet. Therefore, this study set out to evaluate the effects of gluten on IBS symptoms.

Methods

We performed a double-blind randomized placebo-controlled rechallenge trial in a tertiary care hospital with IBS patients who fulfilled the Rome III criteria. Patients with celiac disease and wheat allergy were appropriately excluded. The participants were administered a gluten-free diet for 4 weeks and were asked to complete a symptom-based questionnaire to assess their overall symptoms, abdominal pain, bloating, wind, and tiredness on the visual analog scale (0-100) at the baseline and every week thereafter. The participants who showed improvement were randomly assigned to one of two groups to receive either a placebo (gluten-free breads) or gluten (whole cereal breads) as a rechallenge for the next 4 weeks.

Results

In line with the protocol analysis, 60 patients completed the study. The overall symptom score on the visual analog scale was significantly different between the two groups (P<0.05). Moreover, the patients in the gluten intervention group scored significantly higher in terms of abdominal pain, bloating, and tiredness (P<0.05), and their symptoms worsened within 1 week of the rechallenge.

Conclusions

A gluten diet may worsen the symptoms of IBS patients. Therefore, some form of gluten sensitivity other than celiac disease exists in some of them, and patients with IBS may benefit from gluten restrictions.

Citations

Citations to this article as recorded by  
  • The role of gluten and wheat in irritable bowel syndrome and noncoeliac gluten or wheat sensitivity
    Tom van Gils, Magnus Simrén
    Current Opinion in Gastroenterology.2025; 41(3): 164.     CrossRef
  • Diet, nutraceuticals, and lifestyle interventions for the treatment and management of irritable bowel syndrome
    Zoe N. Memel, Neha D. Shah, Kendall R. Beck
    Nutrition in Clinical Practice.2025;[Epub]     CrossRef
  • Gluten-free grains: Importance, processing and its effect on quality of gluten-free products
    Samandeep Kaur, Kshitiz Kumar, Lochan Singh, Vijay Singh Sharanagat, Prabhat K. Nema, Vijendra Mishra, Bharat Bhushan
    Critical Reviews in Food Science and Nutrition.2024; 64(7): 1988.     CrossRef
  • Indian consensus statements on irritable bowel syndrome in adults: A guideline by the Indian Neurogastroenterology and Motility Association and jointly supported by the Indian Society of Gastroenterology
    Uday C. Ghoshal, Sanjeev Sachdeva, Nitesh Pratap, Arun Karyampudi, Uzma Mustafa, Philip Abraham, Chetan B. Bhatt, Karmabir Chakravartty, Sujit Chaudhuri, Omesh Goyal, Govind K. Makharia, Manas Kumar Panigrahi, Prasanta Kumar Parida, Sudhanshu Patwari, Raj
    Indian Journal of Gastroenterology.2023; 42(2): 249.     CrossRef
  • Current evidence for dietary therapies in irritable bowel syndrome
    Anupam Rej, Hugo A. Penny
    Current Opinion in Gastroenterology.2023; 39(3): 219.     CrossRef
  • The Role of Gluten in Gastrointestinal Disorders: A Review
    Sabrina Cenni, Veronica Sesenna, Giulia Boiardi, Marianna Casertano, Giuseppina Russo, Alfonso Reginelli, Susanna Esposito, Caterina Strisciuglio
    Nutrients.2023; 15(7): 1615.     CrossRef
  • Gluten restriction in irritable bowel syndrome, yes or no?: a GRADE-assessed systematic review and meta-analysis
    Erfan Arabpour, Dorsa Alijanzadeh, Amir Sadeghi, Sina Khoshdel, Azita Hekmatdoost, Hamed Kord-Varkaneh, Mohammad Abdehagh
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Boosting biomedical document classification through the use of domain entity recognizers and semantic ontologies for document representation: The case of gluten bibliome
    Martín Pérez-Pérez, Tânia Ferreira, Anália Lourenço, Gilberto Igrejas, Florentino Fdez-Riverola
    Neurocomputing.2022; 484: 223.     CrossRef
  • Management of bloating
    Jordi Serra
    Neurogastroenterology & Motility.2022;[Epub]     CrossRef
  • Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders
    Anupam Rej, Michael D. E. Potter, Nicholas J. Talley, Ayesha Shah, Gerald Holtmann, David Surendran Sanders
    American Journal of Gastroenterology.2022; 117(6): 958.     CrossRef
  • Diet and irritable bowel syndrome: an update from a UK consensus meeting
    A. Rej, A. Avery, I. Aziz, C. J. Black, R. K. Bowyer, R. L. Buckle, L. Seamark, C. C. Shaw, J. Thompson, N. Trott, M. Williams, D. S. Sanders
    BMC Medicine.2022;[Epub]     CrossRef
  • Belgian consensus on irritable bowel syndrome
    S Kindt, H Louis, H De Schepper, J Arts, P Caenepeel, D De Looze, A Gerkens, T Holvoet, P Latour, T Mahler, F Mokaddem, S Nullens, H Piessevaux, P Poortmans, G Rasschaert, M Surmont, H Vafa, K Van Malderen, T Vanuytsel, F Wuestenberghs, J Tack
    Acta Gastro Enterologica Belgica.2022; 85(2): 360.     CrossRef
  • A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
    Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
    Endocrinología, Diabetes y Nutrición.2021; 68(1): 17.     CrossRef
  • Non-responsive celiac disease may coincide with additional food intolerance/malabsorption, including histamine intolerance
    Wolfgang J. Schnedl, Harald Mangge, Michael Schenk, Dietmar Enko
    Medical Hypotheses.2021; 146: 110404.     CrossRef
  • Non-celiac wheat sensitivity: rationality and irrationality of a gluten-free diet in individuals affected with non-celiac disease: a review
    Consolato Sergi, Vincenzo Villanacci, Antonio Carroccio
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • Personalizing Dietary Therapies For Irritable Bowel Syndrome: What Is Gluten’s Role?
    Anupam Rej, Imran Aziz, David S. Sanders
    Clinical Gastroenterology and Hepatology.2021; 19(11): 2270.     CrossRef
  • A food pyramid, based on a review of the emerging literature, for subjects with inflammatory bowel disease
    Mariangela Rondanelli, Silvia Lamburghini, Milena A. Faliva, Gabriella Peroni, Antonella Riva, Pietro Allegrini, Daniele Spadaccini, Clara Gasparri, Giancarlo Iannello, Vittoria Infantino, Tariq A. Alalwan, Simone Perna, Alessandra Miccono
    Endocrinología, Diabetes y Nutrición (English ed.).2021; 68(1): 17.     CrossRef
  • Histamine Intolerance Originates in the Gut
    Wolfgang J. Schnedl, Dietmar Enko
    Nutrients.2021; 13(4): 1262.     CrossRef
  • Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms
    Annamaria Altomare, Claudia Di Rosa, Elena Imperia, Sara Emerenziani, Michele Cicala, Michele Pier Luca Guarino
    Nutrients.2021; 13(5): 1506.     CrossRef
  • Adherence to treatment of patients with irritable bowel syndrome: state of the issue
    S.A. Sukhanova, A.Yu. Timakova, M.A. Livzan, M.M. Fedorin, Yu.P. Skirdenko, O.V. Gaus, K.A. Andreev, A.V. Gorbenko, M.I. Plinder
    Profilakticheskaya meditsina.2021; 24(8): 101.     CrossRef
  • Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastr
    P. Layer, V. Andresen, H. Allescher, S. C. Bischoff, M. Claßen, S. Elsenbruch, M. Freitag, T. Frieling, M. Gebhard, M. Goebel-Stengel, W. Häuser, G. Holtmann, J. Keller, M. E. Kreis, W. Kruis, J. Langhorst, P. Lynen Jansen, A. Madisch, H. Mönnikes, S. Mül
    Zeitschrift für Gastroenterologie.2021; 59(12): 1323.     CrossRef
  • Nutrition in Patients with Lactose Malabsorption, Celiac Disease, and Related Disorders
    Michele J. Alkalay
    Nutrients.2021; 14(1): 2.     CrossRef
  • Letter: the gluten‐free diet as a bottom‐up approach for irritable bowel syndrome
    Anupam Rej, Rachel Louise Buckle, Christian Charles Shaw, Nick Trott, Imran Aziz, David Surendran Sanders
    Alimentary Pharmacology & Therapeutics.2020; 51(1): 184.     CrossRef
  • Irritable Bowel Syndrome and Gluten-Related Disorders
    Paolo Usai-Satta, Gabrio Bassotti, Massimo Bellini, Francesco Oppia, Mariantonia Lai, Francesco Cabras
    Nutrients.2020; 12(4): 1117.     CrossRef
  • Ernährungsmedizinische Aspekte beim Reizdarmsyndrom – ein Update
    Larissa Hetterich, Andreas Stengel
    Aktuelle Ernährungsmedizin.2020; 45(04): 276.     CrossRef
  • The Two Faces of Wheat
    Herbert Wieser, Peter Koehler, Katharina A. Scherf
    Frontiers in Nutrition.2020;[Epub]     CrossRef
  • Low Fermentable Oligo- Di- and Mono-Saccharides and Polyols (FODMAPs) or Gluten Free Diet: What Is Best for Irritable Bowel Syndrome?
    Massimo Bellini, Sara Tonarelli, Maria Gloria Mumolo, Francesco Bronzini, Andrea Pancetti, Lorenzo Bertani, Francesco Costa, Angelo Ricchiuti, Nicola de Bortoli, Santino Marchi, Alessandra Rossi
    Nutrients.2020; 12(11): 3368.     CrossRef
  • Breaking bread!
    Anupam Rej, Imran Aziz, David Surendran Sanders
    Proceedings of the Nutrition Society.2019; 78(1): 118.     CrossRef
  • Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics
    Elena Scarpato, Renata Auricchio, Francesca Penagini, Angelo Campanozzi, Gian Vincenzo Zuccotti, Riccardo Troncone
    Italian Journal of Pediatrics.2019;[Epub]     CrossRef
  • The overlap of irritable bowel syndrome and noncoeliac gluten sensitivity
    Anupam Rej, David S. Sanders
    Current Opinion in Gastroenterology.2019; 35(3): 199.     CrossRef
  • Gluten Vehicle and Placebo for Non-Celiac Gluten Sensitivity Assessment
    Oscar Gerardo Figueroa-Salcido, Noé Ontiveros, Francisco Cabrera-Chavez
    Medicina.2019; 55(5): 117.     CrossRef
  • The role of diet in irritable bowel syndrome: implications for dietary advice
    A. Rej, I. Aziz, H. Tornblom, D. S. Sanders, M. Simrén
    Journal of Internal Medicine.2019; 286(5): 490.     CrossRef
  • Does Irritable Bowel Syndrome Exist? Identifiable and Treatable Causes of Associated Symptoms Suggest It May Not
    Benjamin I. Brown
    Gastrointestinal Disorders.2019; 1(3): 314.     CrossRef
  • Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm
    Giuseppe Losurdo, Mariabeatrice Principi, Andrea Iannone, Annacinzia Amoruso, Enzo Ierardi, Alfredo Di Leo, Michele Barone
    World Journal of Gastroenterology.2018; 24(14): 1521.     CrossRef
  • Is an enzyme supplement for celiac disease finally on the cards?
    Julia König, Robert J. Brummer
    Expert Review of Gastroenterology & Hepatology.2018; 12(6): 531.     CrossRef
  • Non-celiac gluten sensitivity: people without celiac disease avoiding gluten—is it due to histamine intolerance?
    Wolfgang J. Schnedl, Sonja Lackner, Dietmar Enko, Michael Schenk, Harald Mangge, Sandra J. Holasek
    Inflammation Research.2018; 67(4): 279.     CrossRef
  • Gluten sensitivities and the allergist: Threshing the grain from the husks
    J. G. Burkhardt, A. Chapa‐Rodriguez, S. L. Bahna
    Allergy.2018; 73(7): 1359.     CrossRef
  • Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease
    Berkeley N. Limketkai, Rachel Sepulveda, Tressia Hing, Neha D. Shah, Monica Choe, David Limsui, Shamita Shah
    Scandinavian Journal of Gastroenterology.2018; 53(2): 147.     CrossRef
  • Non‐celiac gluten or wheat sensitivity: It's complicated!
    Maria I. Pinto‐Sanchez, Elena F. Verdu
    Neurogastroenterology & Motility.2018;[Epub]     CrossRef
  • Canadian packaged gluten-free foods are less nutritious than their regular gluten-containing counterparts
    Jennifer A. Jamieson, Mary Weir, Laura Gougeon
    PeerJ.2018; 6: e5875.     CrossRef
  • Consensus document on exclusion diets in irritable bowel syndrome (IBS)
    Francesc Casellas, Rosa Burgos, Ascensión Marcos, Javier Santos, Constanza Ciriza de los Ríos, Álvaro García Manzanares, Isabel Polanco, María Puy Portillo, Antonio Villarino, Beatriz Lema Marqués, María del Carmen Vázquez Alférez
    Revista Española de Enfermedades Digestivas.2018;[Epub]     CrossRef
  • Gluten-Free Diet and Its ‘Cousins’ in Irritable Bowel Syndrome
    Anupam Rej, David Surendran Sanders
    Nutrients.2018; 10(11): 1727.     CrossRef
  • IRRITABLE BOWEL SYNDROME, FOOD INTOLERANCE AND NON- CELIAC GLUTEN SENSITIVITY. A NEW CLINICAL CHALLENGE
    Rosa Leonôra Salerno SOARES
    Arquivos de Gastroenterologia.2018; 55(4): 417.     CrossRef
  • Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting
    Julia König, Savanne Holster, Maaike J. Bruins, Robert J. Brummer
    Scientific Reports.2017;[Epub]     CrossRef
  • The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update
    Carlo Catassi, Armin Alaedini, Christian Bojarski, Bruno Bonaz, Gerd Bouma, Antonio Carroccio, Gemma Castillejo, Laura De Magistris, Walburga Dieterich, Diana Di Liberto, Luca Elli, Alessio Fasano, Marios Hadjivassiliou, Matthew Kurien, Elena Lionetti, Ch
    Nutrients.2017; 9(11): 1268.     CrossRef
  • Irritable bowel syndrome and diet
    Eirini Dimidi, Megan Rossi, Kevin Whelan
    Current Opinion in Clinical Nutrition & Metabolic Care.2017; 20(6): 456.     CrossRef
  • Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!
    Anamaria Cozma-Petruţ, Felicia Loghin, Doina Miere, Dan Lucian Dumitraşcu
    World Journal of Gastroenterology.2017; 23(21): 3771.     CrossRef
  • 8,879 View
  • 112 Download
  • 49 Web of Science
  • 47 Crossref
Close layer
Thirty-day mortality after percutaneous gastrostomy by endoscopic versus radiologic placement: a systematic review and meta-analysis
Joo Hyun Lim, Seung Ho Choi, Changhyun Lee, Ji Yeon Seo, Hae Yeon Kang, Jong In Yang, Su Jin Chung, Joo Sung Kim
Intest Res 2016;14(4):333-342.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.333
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

A percutaneous gastrostomy can be placed either endoscopically (percutaneous endoscopic gastrostomy, PEG) or radiologically (radiologically-inserted gastrostomy, RIG). However, there is no consistent evidence of the safety and efficacy of PEG compared to RIG. Recently, 30-day mortality has become considered as the most important surrogate index for evaluating the safety and efficacy of percutaneous gastrostomy. The aim of this meta-analysis was to compare the 30-day mortality rates between PEG and RIG.

Methods

Major electronic databases (MEDLINE, Embase, Scopus, and Cochrane library) were queried for comparative studies on the two insertion techniques of gastrostomy among adults with swallowing disturbance. The primary outcome was the 30-day mortality rate after gastrostomy insertion. Forest and funnel plots were generated for outcomes using STATA version 14.0.

Results

Fifteen studies (n=2,183) met the inclusion criteria. PEG was associated with a lower risk of 30-day mortality after tube placement compared with RIG (odds ratio, 0.60; 95% confidence interval [CI], 0.38–0.94; P=0.026). The pooled prevalence of 30-day mortality of PEG was 5.5% (95% CI, 4.0%–6.9%) and that of RIG was 10.5% (95% CI, 6.8%–14.3%). No publication bias was noted.

Conclusions

The present meta-analysis demonstrated that PEG is associated with a lower probability of 30-day mortality compared to RIG, suggesting that PEG should be considered as the first choice for long-term enteral tube feeding. Further prospective randomized studies are needed to evaluate and compare the safety of these two different methods of gastrostomy.

Citations

Citations to this article as recorded by  
  • Factors Predicting Major Complications and Mortality in Percutaneous Endoscopic Gastrostomy: 8 Years of Experience of a Tertiary Surgery Center
    Murat Yildirim, Asim Kocabay, Bulent Koca, Ali Ihsan Saglam, Namik Ozkan
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2025;[Epub]     CrossRef
  • Improving 30-day mortality after radiologically inserted gastrostomy tube from 2007 to 2019: A population-based study of 15,605 patients
    Syed Shezal Hussain, Nosheen Umar, Umair Kamran, Benjamin Coupland, Fumi Varyani, Nigel Trudgill
    Clinical Nutrition ESPEN.2025; 66: 381.     CrossRef
  • S3-Leitlinie Heimenterale und heimparenterale Ernährung der Deutschen Gesellschaft für Ernährungsmedizin (DGEM)
    Stephan C. Bischoff, Jann Arends, Christiane Decker-Baumann, Elisabeth Hütterer, Sebastian Koch, Stefan Mühlebach, Ingeborg Roetzer, Andrea Schneider, Claudia Seipt, Ralph Simanek, Zeno Stanga
    Aktuelle Ernährungsmedizin.2024; 49(02): 73.     CrossRef
  • Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy for enteral feeding: A systematic review and meta‐analysis
    Matheus Coelho Meine, Isabela Ho Tusato, Nathalia Hoffmeister, Gilmara Coelho Meine
    Journal of Parenteral and Enteral Nutrition.2024; 48(6): 667.     CrossRef
  • Direct Percutaneous Endoscopic Gastrostomy Versus Radiological Gastrostomy in Patients Unable to Undergo Transoral Endoscopic Pull Gastrostomy
    Divyanshoo R. Kohli, Craig Smith, Omer Chaudhry, Madhav Desai, Dion DePaolis, Prateek Sharma
    Digestive Diseases and Sciences.2023; 68(3): 852.     CrossRef
  • Complications of Percutaneous Radiologic Gastrostomy Among Patients in a Tertiary Care Hospital in Riyadh, Saudi Arabia
    Najla Alrasheed, Haneen S Khair, Renad M Aljohani, Noof M Alharbi, Nahlah N Alotaibi, Shahad F AlEdrees, Aamir Omair
    Cureus.2023;[Epub]     CrossRef
  • A retrospective study of outcomes and the validation of the Sheffield Gastrostomy Score in PEGs, RIGs and PIGs
    Heather Parr, Lloyd Thomas, Prabhsimran Singh, Salma Mohammed, Khin Nu, John S. Kane, Fred Lee, Thomas Welbank, Andrew D. Hopper, Mark E. McAlindon, Elizabeth A. Williams, David S. Sanders
    Scandinavian Journal of Gastroenterology.2023; 58(12): 1542.     CrossRef
  • Endoscopic vs radiologic gastrostomy for enteral feeding: A systematic review and meta-analysis
    Evellin Souza Valentim dos Santos, Guilherme Henrique Peixoto de Oliveira, Diogo Turiani Hourneaux de Moura, Bruno Salomão Hirsch, Roberto Paolo Trasolini, Wanderley Marques Bernardo, Eduardo Guimarães Hourneaux de Moura
    World Journal of Meta-Analysis.2023; 11(6): 277.     CrossRef
  • Outcomes of push and pull percutaneous endoscopic gastrostomy placements in 854 patients: A single‐center study
    Hicham Bouchiba, Maarten A J M Jacobs, Gerd Bouma, Dewkoemar Ramsoekh
    JGH Open.2022; 6(1): 57.     CrossRef
  • Factors affecting late complications of percutaneous endoscopic gastrostomy tube replacement
    Kasenee Tiankanon, Satimai Aniwan, Julalak Karuehardsuwan, Sumitra Wiangngoen, Rungsun Rerknimitr
    Clinical Nutrition ESPEN.2022; 49: 378.     CrossRef
  • The Outcomes of Nutritional Support Techniques in Patients with Gastrointestinal Cancers
    Vlad-Alexandru Ionescu, Gina Gheorghe, Ruxandra Oprita, Madalina Stan-Ilie, Raluca-Ioana Dascalu, Ondin Zaharia, Viorel Jinga, Camelia Cristina Diaconu, Gabriel Constantinescu
    Gastroenterology Insights.2022; 13(3): 245.     CrossRef
  • Improving 30-day mortality after PEG tube placement in England from 2007 to 2019: a retrospective national cohort analysis of 87,862 patients
    Umair Kamran, Pui Chi Lee, Ben Coupland, Abdullah Abbasi, Helen Steed, Sissi Ispoglou, Fumi Varyani, Nigel Trudgill
    Gastrointestinal Endoscopy.2022; 96(6): 943.     CrossRef
  • Outcomes following percutaneous endoscopic gastrostomy versus fluoroscopic procedures in the Medicare population
    Samantha Maasarani, Syed I. Khalid, Chantal Creighton, Athena J. Manatis-Lornell, Aaron L. Wiegmann, Samantha L. Terranella, Nicholas J. Skertich, Laura DeCesare, Edie Y. Chan
    Surgery Open Science.2021; 3: 2.     CrossRef
  • Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment
    Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
    Gastrointestinal Endoscopy.2021; 93(5): 1077.     CrossRef
  • Laparoscopic vs open insertion of feeding gastrostomy tube in adults with head and neck cancers: A case‐matched comparative study
    Balqees Omari, Huthaifa Asmer, Hani Al‐Najjar, Issa Mohamad, Omar Al‐Saraireh, Basil J. Ammori
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • Percutaneous endoscopic gastrostomy
    Xudong Liu, Zhengqiang Yang, Shun He, Guiqi Wang
    International Journal of Gastrointestinal Intervention.2021; 10(2): 42.     CrossRef
  • Scheduled percutaneous endoscopic gastrostomy tube replacement did not reduce PEG-related complications
    Wisam Sbeit, Anas Kadah, Amir Shahin, Samer Shbat, Moeen Sbeit, Tawfik Khoury
    Scandinavian Journal of Gastroenterology.2021; 56(11): 1386.     CrossRef
  • Comparative Safety of Endoscopic vs Radiological Gastrostomy Tube Placement: Outcomes From a Large, Nationwide Veterans Affairs Database
    Divyanshoo R. Kohli, Kevin F. Kennedy, Madhav Desai, Prateek Sharma
    American Journal of Gastroenterology.2021; 116(12): 2367.     CrossRef
  • ESPEN guideline on home enteral nutrition
    Stephan C. Bischoff, Peter Austin, Kurt Boeykens, Michael Chourdakis, Cristina Cuerda, Cora Jonkers-Schuitema, Marek Lichota, Ibolya Nyulasi, Stéphane M. Schneider, Zeno Stanga, Loris Pironi
    Clinical Nutrition.2020; 39(1): 5.     CrossRef
  • Technical success rate and safety of radiologically inserted gastrostomy versus percutaneous endoscopic gastrostomy in motor neuron disease patients undergoing: A systematic review and meta-analysis
    Tian-wen Yuan, Yang He, Sai-bo Wang, Peng Kong, Jun Cao
    Journal of the Neurological Sciences.2020; 410: 116622.     CrossRef
  • Predictors for 30-day mortality and complications following radiologically inserted gastrostomies: a single centre, large cohort review
    J. Delf, S. Jepson, S. Ramachandran, M. Elabassy, B. Morgan, R. Kenningham, J.H. Mullineux, J.A. Stephenson
    Clinical Radiology.2020; 75(5): 375.     CrossRef
  • Gastropexy can be as safe as conventional percutaneous endoscopic gastrostomy (PEG), and biomarkers do not predict short-term or long-term outcomes: a 7-year follow-up audit
    Ross J Porter, Alastair W McKinlay, Emma L Metcalfe
    Frontline Gastroenterology.2020; 11(5): 364.     CrossRef
  • Early versus Delayed Feeding after Percutaneous Endoscopic Gastrostomy Placement in Children: A Meta-Analysis
    Jun Watanabe, Kazuhiko Kotani
    Children.2020; 7(9): 124.     CrossRef
  • Reducing 30-day post gastrostomy insertion mortality with a feeding issues multidisciplinary team meeting
    A. Bond, T. Conley, J. Fiske, V. Raymond, A. Young, P. Collins, M. Dibb, P.J. Smith
    Clinical Nutrition ESPEN.2020; 40: 282.     CrossRef
  • Nutritional Support of Cancer Patients without Oral Feeding: How to Select the Most Effective Technique?
    Gonçalo Nunes, Jorge Fonseca, Ana Teresa Barata, Mário Dinis-Ribeiro, Pedro Pimentel-Nunes
    GE - Portuguese Journal of Gastroenterology.2020; 27(3): 172.     CrossRef
  • Retrospective comparison of outcomes and associated complications between large bore radiologically inserted gastrostomy tube types
    David J. Tischfield, Gregory J. Nadolski, Stephen J. Hunt, Maxim Itkin, Richard D. Shlansky-Goldberg, Terence P. Gade
    Abdominal Radiology.2019; 44(1): 318.     CrossRef
  • Percutaneous endoscopic gastrostomy for enteral nutrition: a 5-year clinical experience with 324 patients
    Ezekiel W. Toh Yoon, Kaori Yoneda, Kazuki Nishihara
    Minerva Gastroenterologica e Dietologica.2019;[Epub]     CrossRef
  • Simple Bedside Predictors of Survival after Percutaneous Gastrostomy Tube Insertion
    Wisam Sbeit, Anas Kadah, Amir Mari, Mahmud Mahamid, Tawfik Khoury
    Canadian Journal of Gastroenterology and Hepatology.2019; 2019: 1.     CrossRef
  • Risk factors for complications and mortality of percutaneous endoscopic gastrostomy insertion
    Gyu Young Pih, Hee Kyong Na, Ji Yong Ahn, Kee Wook Jung, Do Hoon Kim, Jeong Hoon Lee, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
    BMC Gastroenterology.2018;[Epub]     CrossRef
  • A Systematic Review and Meta-Analysis on Outcomes and Complications of Percutaneous Endoscopic Versus Radiologic Gastrostomy for Enteral Feeding
    Denise Strijbos, Daniel Keszthelyi, Roel M.M. Bogie, Lennard P.L. Gilissen, Martin Lacko, Janneke G.J. Hoeijmakers, Christiaan van der Leij, Rogier de Ridder, Michiel W. de Haan, Ad A.M. Masclee
    Journal of Clinical Gastroenterology.2018; 52(9): 753.     CrossRef
  • Percutaneous Endoscopic Transgastric Jejunostomy (PEG‐J) Tube Placement for Levodopa‐Carbidopa Intrajejunal Gel Therapy in the Interventional Radiology Suite: A Long‐term Follow‐up
    Maria Valeria Saddi, Marianna Sarchioto, Giulia Serra, Daniela Murgia, Valeria Ricchi, Marta Melis, Roberta Arca, Pierpaolo Carreras, Loredana Sitzia, Sandro Zedda, Giovanni Dui, Rosario Rossi, Anna Ticca, Maurizio Melis, Giovanni Cossu
    Movement Disorders Clinical Practice.2018; 5(2): 191.     CrossRef
  • Percutaneous Radiologically-Guided Gastrostomy (PRG): Safety, Efficacy and Trends in a Single Institution
    Gerard ZX Low, Chow Wei Too, Yen Yeong Poh, Richard HG Lo, Bien Soo Tan, Apoorva Gogna, Farah Gillan Irani, Kiang Hiong Tay
    Annals of the Academy of Medicine, Singapore.2018; 47(11): 494.     CrossRef
  • 7,339 View
  • 82 Download
  • 37 Web of Science
  • 32 Crossref
Close layer
Surgical management of inflammatory bowel disease in China: a systematic review of two decades
Qiao Yu, Ren Mao, Lei Lian, Siew chien Ng, Shenghong Zhang, Zhihui Chen, Yanyan Zhang, Yun Qiu, Baili Chen, Yao He, Zhirong Zeng, Shomron Ben-Horin, Xinming Song, Minhu Chen
Intest Res 2016;14(4):322-332.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.322
AbstractAbstract PDFSupplementary MaterialPubReader
<b>Background/Aims</b><br/>

The past decades have seen increasing incidence and prevalence of inflammatory bowel disease (IBD) in China. This article aimed to summarize the current status and characteristics of surgical management for IBD in China.

Methods

We searched PubMed, Embase, and Chinese databases from January 1, 1990 to July 1, 2014 for all relevant studies on the surgical treatment IBD in China. Eligible studies with sufficient defined variables were further reviewed for primary and secondary outcome measures.

Results

A total of 74 studies comprising 2,007 subjects with Crohn's disease (CD) and 1,085 subjects with ulcerative colitis (UC) were included. The percentage of CD patients misdiagnosed before surgery, including misdiagnosis as appendicitis or UC, was 50.8%±30.9% (578/1,268). The overall postoperative complication rate was 22.3%±13.0% (267/1,501). For studies of UC, the overall postoperative complication rate was 22.2%±27.9% (176/725). In large research centers (n>50 surgical cases), the rates of emergency operations for CD (P=0.032) and in-hospital mortalities resulting from both CD and UC were much lower than those in smaller research centers (n≤50 surgical cases) (P=0.026 and P <0.001, respectively). Regarding the changes in CD and UC surgery over time, postoperative complications (P=0.045 for CD; P=0.020 for UC) and postoperative in-hospital mortality (P=0.0002 for CD; P=0.0160 for UC) both significantly improved after the year 2010.

Conclusions

The surgical management of IBD in China has improved over time. However, the rates of misdiagnosis and postoperative complications over the past two decades have remained high. Large research centers were found to have relatively better capacity for surgical management than the smaller ones. Higher quality prospective studies are needed in China.

Citations

Citations to this article as recorded by  
  • Carbon monoxide produced by HO-1 upregulation is the main factor behind the abnormal motility seen in experimental ulcerative colitis in mice
    Mengchao Zhao, Yaru Lei, Mengyuan Wang, Yixin Chen, Shaozhang Hou, Xinyuan Dai, Di Gao, Yudan Liu, Bruno Mazet, Lei Sha
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2025; 328(3): G311.     CrossRef
  • Epidemiological research, burden, and clinical advances of inflammatory bowel disease in China
    Hong Yang, Jiaming Qian
    Chinese Medical Journal.2024; 137(9): 1009.     CrossRef
  • Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
    Zerong Cai, Xiaosheng He, Jianfeng Gong, Peng Du, Wenjian Meng, Wei Zhou, Jinbo Jiang, Bin Wu, Weitang Yuan, Qi Xue, Lianwen Yuan, Jinhai Wang, Jiandong Tai, Jie Liang, Weiming Zhu, Ping Lan, Xiaojian Wu
    Intestinal Research.2023; 21(2): 235.     CrossRef
  • Differences in inflammatory bowel diseases between East and West: a Chinese perspective
    Guanglin Cui, Junling Li, Hanzhe Liu, Jann-Birger Laugsand, Zhanju Liu
    Journal of Public Health.2021; 29(1): 19.     CrossRef
  • Diagnostic and Predictive Value of Immune-Related Genes in Crohn’s Disease
    Bing Yu, Yi-xin Yin, Yan-ping Tang, Kang-lai Wei, Zhi-gang Pan, Ke-Zhi Li, Xian-wen Guo, Bang-li Hu
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Role of a multidisciplinary team (MDT) in the diagnosis, treatment, and outcomes of inflammatory bowel disease: a single Chinese center's experience
    Qiang Wu, Xuehong Wang, Feng Wu, Dehong Peng, Guotao Wu, Lichao Yang, Lianwen Yuan
    BioScience Trends.2021; 15(3): 171.     CrossRef
  • MANAGEMENT OF ILEOCECAL CROHN’S DISEASE DURING SURGICAL TREATMENT FOR ACUTE APPENDICITIS: A SYSTEMATIC REVIEW
    Abel Botelho QUARESMA, Eron Fabio MIRANDA, Paulo Gustavo KOTZE
    Arquivos de Gastroenterologia.2021; 58(4): 560.     CrossRef
  • Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study
    Yun Qiu, Baili Chen, Yufei Li, Shanshan Xiong, Shenghong Zhang, Yao He, Zhirong Zeng, Shomron Ben-Horin, Minhu Chen, Ren Mao
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China
    Sanskriti Varma, Jun Hu, Ambar Mehta, Yiran Song, Angela Park, Min Zhi, Susan Hutfless
    JGH Open.2019; 3(3): 234.     CrossRef
  • Can molecular stratification improve the treatment of inflammatory bowel disease?
    Claire Wang, Hannah M. Baer, Daniel R. Gaya, Robert J.B. Nibbs, Simon Milling
    Pharmacological Research.2019; 148: 104442.     CrossRef
  • Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate‑induced ulcerative colitis in mice
    Zhaoyang Liu, Wenbo Xie, Mingru Li, Jing Liu, Xiao Liang, Tao Li
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
    Seong Ran Jeon
    Gut and Liver.2017; 11(2): 171.     CrossRef
  • 6,942 View
  • 75 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Narrow-band imaging with magnifying endoscopy for Peyer's patches is useful in predicting the recurrence of remissive patients with ulcerative colitis
Satoshi Hiyama, Hideki Iijima, Syoichiro Kawai, Akira Mukai, Eri Shiraishi, Shuko Iwatani, Toshio Yamaguchi, Manabu Araki, Yoshito Hayashi, Shinichiro Shinzaki, Tsunekazu Mizushima, Masahiko Tsujii, Tetsuo Takehara
Intest Res 2016;14(4):314-321.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.314
AbstractAbstract PDFSupplementary MaterialPubReader
<b>Background/Aims</b><br/>

Peyer's patches (PPs) are aggregates of lymphoid follicles that are mainly located in the distal ileum; they play a major role in mucosal immunity. We recently reported that patients with ulcerative colitis (UC) have alterations in PPs that can be detected using narrow-band imaging with magnifying endoscopy (NBI-ME). However, the usefulness of NBI-ME in UC treatment as a whole is still unknown.

Methods

We collected NBI-ME images of PPs from 67 UC patients who had undergone ileocolonoscopy. We evaluated changes in the villi using the "villi index," which is based on three categories: irregular formation, hyperemia, and altered vascular network pattern. The patients were divided into two groups on the basis of villi index: low (L)- and high (H)-types. We then determined the correlation between morphological alteration of the PPs and various clinical characteristics. In 52 patients who were in clinical remission, we also analyzed the correlation between NBI-ME findings of PPs and clinical recurrence.

Results

The time to clinical recurrence was significantly shorter in remissive UC patients with H-type PPs than in those with L-type PPs (P<0.01). Moreover, PP alterations were not correlated with age, sex, disease duration, clinical activity, endoscopic score, or extent of disease involvement. Multivariate analysis revealed that the existence of H-type PPs was an independent risk factor for clinical recurrence (hazard ratio, 3.3; P<0.01).

Conclusions

UC patients with morphological alterations in PPs were at high risk of clinical relapse. Therefore, to predict the clinical course of UC, it may be useful to evaluate NBI-ME images of PPs.

Citations

Citations to this article as recorded by  
  • Possible Role of Image-Enhanced Endoscopy in the Evaluation of Mucosal Healing of Ulcerative Colitis
    Minoru Matsuura, Daisuke Saito, Jun Miyoshi, Tadakazu Hisamatsu
    Digestion.2023; 104(1): 42.     CrossRef
  • Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study
    Satoshi Hiyama, Hideki Iijima, Yuko Sakakibara, Takuya Yamada, Akira Mukai, Yuriko Otake, Toshio Yamaguchi, Manabu Araki, Shoichiro Kawai, Yoshiki Tsujii, Takahiro Inoue, Yoshito Hayashi, Shinichiro Shinzaki, Tetsuo Takehara
    Journal of Gastroenterology and Hepatology.2020; 35(7): 1143.     CrossRef
  • Can narrow-band imaging of Peyer's patches predict the recurrence of ulcerative colitis?
    Yoon Jae Kim
    Intestinal Research.2016; 14(4): 295.     CrossRef
  • 7,032 View
  • 73 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease
Hui Won Jang, Hyun Sook Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Intest Res 2016;14(4):305-313.   Published online October 17, 2016
DOI: https://doi.org/10.5217/ir.2016.14.4.305
AbstractAbstract PDFPubReader
<b>Background/Aims</b><br/>

Several studies have found that the measurement of fecal calprotectin is useful for the early diagnosis of inflammatory bowel disease (IBD). We compared the effectiveness of three different fecal calprotectin kits for initial diagnosis in patients with suspected IBD.

Methods

We enrolled 31 patients with IBD (18 Crohn's disease [CD], 11 ulcerative colitis [UC], and two intestinal Behçet's disease), five with irritable bowel syndrome (IBS), and five with other colitis (four infectious colitis and one intestinal tuberculosis). Diagnosis was based on clinical, laboratory, and endoscopic examinations. Fecal samples were obtained at the first diagnosis and calprotectin levels were measured using three different kits (Quantum Blue® Calprotectin, EliA™ Calprotectin, and RIDASCREEN® Calprotectin).

Results

The overall accuracy for differentiating IBD from IBS or other colitis was 94% and 91%, respectively, for Quantum Blue® (cutoff, 50 µg/g); 92% and 89%, respectively, for EliA™ (cutoff, 50 µg/g); and 82% and 76%, respectively, for RIDASCREEN® (cutoff, 50 µg/g). In patients with CD, the results of Quantum Blue® Calprotectin and EliA™ Calprotectin correlated significantly with levels of the Crohn's disease activity index (Spearman's rank correlation coefficient, r=0.66 and r=0.49, respectively). In patients with UC, the results of EliA™ Calprotectin correlated significantly with the Mayo score (r=0.70).

Conclusions

Fecal calprotectin measurement is useful for the identification of IBD. The overall accuracies of the three fecal calprotectin kits are comparable.

Citations

Citations to this article as recorded by  
  • Network pharmacology analysis and animal experiment validation of inflammation inhibition by Swertiamarin in treating Ulcerative colitis
    Tang Jiafeng, Wang Lijuan, Wei Lan, You Yiqing, Yang Shiyu, Zeng Tao, Dang Tingting, Sun Haoli, Li Xiaoshan, Zhang Yan
    Naunyn-Schmiedeberg's Archives of Pharmacology.2025;[Epub]     CrossRef
  • Values of serum intestinal fatty acid-binding protein, fecal calprotectin, and fecal human β-defensin 2 for predicting necrotizing enterocolitis
    Sujia Liu, Yongle Liu, Shuhua Lai, Yingling Xie, Wenlong Xiu, Changyi Yang
    BMC Pediatrics.2024;[Epub]     CrossRef
  • Multimodal Ultrasound Technology Combined with Fecal Calprotectin Assessment in Clinical Studies of Inflammatory Bowel Disease
    泊辛 陈
    Advances in Clinical Medicine.2024; 14(07): 1110.     CrossRef
  • The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
    Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
    Intestinal Research.2021; 19(1): 62.     CrossRef
  • The utility of faecal and urine biomarkers for small bowel diseases
    M.S. Ismail, Serhiy Semenov, Deirdre McNamara
    Current Opinion in Gastroenterology.2021; 37(3): 284.     CrossRef
  • A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease
    Jong-Mi Lee, Joo Hee Jang, Ji Hyeong Ryu, Jaeeun Yoo, Bo-In Lee, Seung-Jun Kim, Eun-Jee Oh, Hsu-Heng Yen
    PLOS ONE.2021; 16(8): e0255974.     CrossRef
  • Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
    Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
    Medicine.2021; 100(34): e27065.     CrossRef
  • Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn’s Disease Based on Serum Levels of Proteins
    Geert D’Haens, Orlaith Kelly, Robert Battat, Mark S. Silverberg, David Laharie, Edouard Louis, Edoardo Savarino, Giorgia Bodini, Andres Yarur, Brigid S. Boland, Waqqas Afif, Xiao-jun Li, Michael Hale, Jessica Ho, Venkateswarlu Kondragunta, Benjamin Huang,
    Gastroenterology.2020; 158(3): 515.     CrossRef
  • Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations
    Emilio J. Laserna-Mendieta, Alfredo J. Lucendo
    Clinical Chemistry and Laboratory Medicine (CCLM).2019; 57(9): 1295.     CrossRef
  • Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease?
    Christopher Ma, Robert Battat, Claire E. Parker, Reena Khanna, Vipul Jairath, Brian Gordon Feagan
    Expert Review of Gastroenterology & Hepatology.2019; 13(4): 319.     CrossRef
  • Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
    Parambir S. Dulai, Laurent Peyrin-Biroulet, Silvio Danese, Bruce E. Sands, Axel Dignass, Dan Turner, Gerassimos Mantzaris, Juergen Schölmerich, Jean-Yves Mary, Walter Reinisch, William J. Sandborn
    Gastroenterology.2019; 157(4): 1032.     CrossRef
  • Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy
    Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke
    BMJ Open.2019; 9(3): e027428.     CrossRef
  • Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes
    Tom Nilsen, Siri Helen Haugen, Anders Larsson
    Health Science Reports.2018;[Epub]     CrossRef
  • Fecal Immunochemical Test and Fecal Calprotectin Measurement Are Noninvasive Monitoring Tools for Predicting Endoscopic Activity in Patients with Ulcerative Colitis
    Ji Young Chang, Jae Hee Cheon
    Gut and Liver.2018; 12(2): 117.     CrossRef
  • Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease
    Cristina Verdejo, Daniel Hervías, Óscar Roncero, Ángel Arias, Abdelmouneim Bouhmidi, Rufo Lorente, Irina Salueña, Alfredo J. Lucendo
    European Journal of Gastroenterology & Hepatology.2018; 30(12): 1521.     CrossRef
  • Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring
    Shu-Chen Wei, Chien-Chih Tung, Meng-Tzu Weng, Jau-Min Wong
    Intestinal Research.2018; 16(4): 546.     CrossRef
  • Serum Adipocytokine Levels as Surrogate Markers for Disease Activity of Crohn’s Disease
    Su Hwan Kim, Seung Hyeon Jang, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, You Sun Kim, Dong Soo Han, Joo Sung Kim
    The American Journal of the Medical Sciences.2017; 353(5): 439.     CrossRef
  • Fecal biomarkers in inflammatory bowel disease: how, when and why?
    Paula Ministro, Diana Martins
    Expert Review of Gastroenterology & Hepatology.2017; 11(4): 317.     CrossRef
  • Could fecal calprotectin enter mainstream use for diagnosing and monitoring inflammatory bowel disease?
    Shu Chen Wei
    Intestinal Research.2016; 14(4): 293.     CrossRef
  • 8,468 View
  • 76 Download
  • 18 Web of Science
  • 19 Crossref
Close layer
Characteristics and outcomes of endoscopically resected colorectal cancers that arose from sessile serrated adenomas and traditional serrated adenomas
Ji Yeon Seo, Seung Ho Choi, Jaeyoung Chun, Changhyun Lee, Ji Min Choi, Eun Hyo Jin, Sung Wook Hwang, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim
Intest Res 2016;14(3):270-279.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.270
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The efficacy and safety of endoscopic resection of colorectal cancer derived from sessile serrated adenomas or traditional serrated adenomas are still unknown. The aims of this study were to verify the characteristics and outcomes of endoscopically resected early colorectal cancers developed from serrated polyps.

Methods

Among patients who received endoscopic resection of early colorectal cancers from 2008 to 2011, cancers with documented pre-existing lesions were included. They were classified as adenoma, sessile serrated adenoma, or traditional serrated adenoma according to the baseline lesions. Clinical characteristics, pathologic diagnosis, and outcomes were reviewed.

Results

Overall, 208 colorectal cancers detected from 198 patients were included: 198 with adenoma, five with sessile serrated adenoma, and five with traditional serrated adenoma. The sessile serrated adenoma group had a higher prevalence of high-grade dysplasia (40.0% vs. 25.8%, P<0.001) than the adenoma group. During follow-up, local recurrence did not occur after endoscopic resection of early colorectal cancers developed from serrated polyps. In contrast, two cases of metachronous recurrence were detected within a short follow-up period.

Conclusions

Cautious observation and early endoscopic resection are recommended when colorectal cancer from serrated polyp is suspected. Colorectal cancers from serrated polyp can be treated successfully with endoscopy.

Citations

Citations to this article as recorded by  
  • Small sessile serrated polyps might not be at a higher risk for future advanced neoplasia than low-risk adenomas or polyp-free groups
    Eun Hyo Jin, Ji Yeon Seo, Jung Ho Bae, Jooyoung Lee, Ji Min Choi, Yoo Min Han, Joo Hyun Lim
    Scandinavian Journal of Gastroenterology.2022; 57(1): 99.     CrossRef
  • The incidence and risk factors of sessile serrated adenomas in left side colon cancer patients after curative surgery
    Myung Hee Kim, Hee Seok Moon, In Sun Kwon, Ju Seok Kim, Sun Hyung Kang, Jae Kyu Sung, Eaum Seok Lee, Seok Hyun Kim, Byung Seok Lee, Hyun Yong Jeong
    Medicine.2020; 99(29): e20799.     CrossRef
  • Improved Real-Time Optical Diagnosis of Colorectal Polyps Following a Comprehensive Training Program
    Jung Ho Bae, Changhyun Lee, Hae Yeon Kang, Min-Sun Kwak, Eun Young Doo, Ji Yeon Seo, Ji Hyun Song, Sun Young Yang, Jong In Yang, Seon Hee Lim, Jeong Yoon Yim, Joo Hyun Lim, Goh Eun Chung, Su Jin Chung, Eun Hyo Jin, Boram Park, Joo Sung Kim
    Clinical Gastroenterology and Hepatology.2019; 17(12): 2479.     CrossRef
  • Clinical outcomes of surveillance colonoscopy for patients with sessile serrated adenoma
    Sung Jae Park, Hyuk Yoon, In Sub Jung, Cheol Min Shin, Young Soo Park, Na Young Kim, Dong Ho Lee
    Intestinal Research.2018; 16(1): 134.     CrossRef
  • Surveillance colonoscopy in patients with sessile serrated adenoma
    Ji Hyung Nam, Hyoun Woo Kang
    Intestinal Research.2018; 16(3): 502.     CrossRef
  • Identification of risk factors for sessile and traditional serrated adenomas of the colon by using big data analysis
    Jeung Hui Pyo, Sang Yun Ha, Sung Noh Hong, Dong Kyung Chang, Hee Jung Son, Kyoung‐Mee Kim, Hyeseung Kim, Kyunga Kim, Jee Eun Kim, Yoon‐Ho Choi, Young‐Ho Kim
    Journal of Gastroenterology and Hepatology.2018; 33(5): 1039.     CrossRef
  • Endoscopic Resection of Cecal Polyps Involving the Appendiceal Orifice: A KASID Multicenter Study
    Eun Mi Song, Hyo-Joon Yang, Hyun Jung Lee, Hyun Seok Lee, Jae Myung Cha, Hyun Gun Kim, Yunho Jung, Chang Mo Moon, Byung Chang Kim, Jeong-Sik Byeon
    Digestive Diseases and Sciences.2017; 62(11): 3138.     CrossRef
  • Is colorectal cancer screening necessary before 50 years of age?
    Yoon Suk Jung
    Intestinal Research.2017; 15(4): 550.     CrossRef
  • Derivation and validation of a risk scoring model to predict advanced colorectal neoplasm in adults of all ages
    Hyo‐Joon Yang, Sungkyoung Choi, Soo‐Kyung Park, Yoon Suk Jung, Kyu Yong Choi, Taesung Park, Ji Yeon Kim, Dong Il Park
    Journal of Gastroenterology and Hepatology.2017; 32(7): 1328.     CrossRef
  • Risk factors of missed colorectal lesions after colonoscopy
    Jeonghun Lee, Sung Won Park, You Sun Kim, Kyung Jin Lee, Hyun Sung, Pil Hun Song, Won Jae Yoon, Jeong Seop Moon
    Medicine.2017; 96(27): e7468.     CrossRef
  • 6,659 View
  • 57 Download
  • 11 Web of Science
  • 10 Crossref
Close layer
Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer
Sawan Bopanna, Maitreyee Roy, Prasenjit Das, S Dattagupta, V Sreenivas, V Pratap Mouli, Saurabh Kedia, Rajan Dhingra, Rajesh Pradhan, N Suraj Kumar, Dawesh P Yadav, Govind Makharia, Vineet Ahuja
Intest Res 2016;14(3):264-269.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.264
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Recent data suggest that the incidence of ulcerative colitis (UC) related colorectal cancer (CRC) in India is similar to that of West. The optimum method for surveillance is still a debate. Surveillance with random biopsies has been the standard of care, but is a tedious process. We therefore undertook this study to assess the yield of random biopsy in dysplasia surveillance.

Methods

Between March 2014 and July 2015, patients of UC attending the Inflammatory Bowel Disease clinic at the All India Institute of Medical Sciences with high risk factors for CRC like duration of disease >15 years and pancolitis, family history of CRC, primary sclerosing cholangitis underwent surveillance colonoscopy for dysplasia. Four quadrant random biopsies at 10 cm intervals were taken (33 biopsies). Two pathologists examined specimens for dysplasia, and the yield of dysplasia was calculated.

Results

Twenty-eight patients were included. Twenty-six of these had pancolitis with a duration of disease greater than 15 years, and two patients had associated primary sclerosing cholangis. No patient had a family history of CRC. The mean age at onset of disease was 28.89±8.73 years and the duration of disease was 19.00±8.78 years. Eighteen patients (64.28%) were males. A total of 924 biopsies were taken. None of the biopsies revealed any evidence of dysplasia, and 7/924 (0.7%) were indefinite for dysplasia.

Conclusions

Random biopsy for surveillance in longstanding extensive colitis has a low yield for dysplasia and does not suffice for screening. Newer techniques such as chromoendoscopy-guided biopsies need greater adoption.

Citations

Citations to this article as recorded by  
  • Interlukin-23 inhibitors as an induction and maintenance therapy for moderate to severe ulcerative colitis: a systematic review and meta‑analysis of randomized controlled trials
    Omar Saab, Hasan Al-Obaidi, Marwah Algodi, Asma Algodi, Yasir Rashid, Alhareth Al-Sagban, Hayder Alamily, Nooraldin Merza, Layth Alzubaidy, Andrew DuPont
    Inflammation Research.2025;[Epub]     CrossRef
  • Etrolizumab as an induction and maintenance therapy for ulcerative colitis: A systematic review and meta‐analysis of randomized controlled trials
    Othman Saleh, Mohamed T. Abuelazm, Islam Mohamed, Alaa Ramadan, Mohammad Assaf, Ahmad Alzoubi, Majd M. AlBarakat, Basel Abdelazeem
    JGH Open.2024;[Epub]     CrossRef
  • Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
    Arshdeep Singh, Vandana Midha, Vikram Narang, Saurabh Kedia, Ramit Mahajan, Pavan Dhoble, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Ashish Tripathi, Shivam Kalra, Narender Pal Jain, Namita Bansal, Rupa Banerjee, Devendra Desai, Usha Dutta, Vineet Ahuja
    Intestinal Research.2023; 21(4): 452.     CrossRef
  • Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question
    Roberto Gabbiadini, Ferdinando D’Amico, Alessandro De Marco, Maria Terrin, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Gionata Fiorino, Silvio Danese
    Journal of Clinical Medicine.2022; 11(3): 509.     CrossRef
  • Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology
    Arianna Dal Buono, Roberto Gabbiadini, Federica Furfaro, Marjorie Argollo, Thaís Viana Tavares Trigo, Alessandro Repici, Giulia Roda
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Heterogeneity of Colorectal Cancer Progression: Molecular Gas and Brakes
    Federica Gaiani, Federica Marchesi, Francesca Negri, Luana Greco, Alberto Malesci, Gian Luigi de’Angelis, Luigi Laghi
    International Journal of Molecular Sciences.2021; 22(10): 5246.     CrossRef
  • Histopathological study of endoscopic biopsies of large intestine
    Manjiri N Karandikar, Purva Kulkarni, Smita Mulay, R C Nimbergi, N S Mani
    Indian Journal of Pathology and Oncology.2021; 8(3): 340.     CrossRef
  • Is histological remission of ulcerative colitis achievable?
    Oleg V. Knyazev, Anna V. Kagramanova, Sergei G. Khomeriki, Asfold I. Parfenov
    Terapevticheskii arkhiv.2021; 93(8): 975.     CrossRef
  • A Systematic Review and Meta-Analysis on the Association between Inflammatory Bowel Disease Family History and Colorectal Cancer
    Hadis Najafimehr, Hamid Asadzadeh Aghdaei, Mohamad Amin Pourhoseingholi, Hamid Mohaghegh Shalmani, Amir Vahedian-Azimi, Matthew Kroh, Mohammad Reza Zali, Amirhossein Sahebkar, Muhammad Naeem
    Gastroenterology Research and Practice.2021; 2021: 1.     CrossRef
  • Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
    Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
    Intestinal Research.2021; 19(4): 419.     CrossRef
  • Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy
    Oleg V. Knyazev, Sergey G. Khomeriki, Аnna V. Kagramanova, Albina A. Lishchinskaya, Olga A. Smirnova, Karina K. Noskova, Asfold I. Parfenov
    Terapevticheskii arkhiv.2021; 93(12): 1435.     CrossRef
  • Discovery and Validation of Methylation Biomarkers for Ulcerative Colitis Associated Neoplasia
    Andrew D Beggs, Jonathan James, Germaine Caldwell, Toby Prout, Mark P Dilworth, Phillipe Taniere, Tariq Iqbal, Dion G Morton, Glenn Matthews
    Inflammatory Bowel Diseases.2018; 24(7): 1503.     CrossRef
  • Can histologic remission be a better prognostic factor and therapeutic target beyond endoscopic mucosal healing in patients with ulcerative colitis?
    Hyo Jun Ahn, Sang-Bum Kang
    Intestinal Research.2018; 16(1): 1.     CrossRef
  • The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment
    Louise C. Connell, José Mauricio Mota, Maria Ignez Braghiroli, Paulo M. Hoff
    Current Treatment Options in Oncology.2017;[Epub]     CrossRef
  • Screening strategy for colorectal cancer according to risk
    Dong Soo Han
    Journal of the Korean Medical Association.2017; 60(11): 893.     CrossRef
  • 6,715 View
  • 59 Download
  • 15 Web of Science
  • 15 Crossref
Close layer
Change in the diagnosis of inflammatory bowel disease: a hospital-based cohort study from Korea
Ho-Su Lee, Jaewon Choe, Hyo Jeong Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
Intest Res 2016;14(3):258-263.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.258
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Accurately diagnosing inflammatory bowel disease (IBD) remains a challenge, but is crucial for providing proper management for affected patients. The aim of the present study was to evaluate the frequency of change in diagnosis in Korean patients who were referred to our institution with a diagnosis of IBD.

Methods

We enrolled 1,444 patients diagnosed with ulcerative colitis (UC) and 1,452 diagnosed with Crohn's disease (CD), who had been referred to the Asan Medical Center between January 2010 and December 2014. These patients were assessed and subsequently classified as having UC, CD, indeterminate colitis, possible IBD, or non-IBD.

Results

During a median follow-up of 15.9 months, 400 of the 2,896 patients (13.8%) analyzed in this study experienced a change in diagnosis. A change in diagnosis from UC to CD, or vice-versa, was made in 24 of 1,444 patients (1.7%) and 23 of 1,452 patients (1.6%), respectively. A change to a non-IBD diagnosis was the most common modification; 7.5% (108 of 1444) and 12.7% (184 of 1452) of the patients with a referral diagnosis of UC and CD, respectively, were reclassified as having non-IBD. Among the 292 patients who were ultimately determined not to have IBD, 135 (55 UC and 80 CD cases) had received IBD-related medication.

Conclusions

There are diagnostic uncertainties and difficulties in relation to IBD. Therefore, precise assessment and systematic follow-up are essential in the management of this condition.

Citations

Citations to this article as recorded by  
  • Diagnosis change in pediatric inflammatory bowel disease
    Harold Duarte, Adrienne Stolfi, Courtney McCall, Shehzad Saeed, Kelly Sandberg
    Journal of Pediatric Gastroenterology and Nutrition.2024; 78(3): 623.     CrossRef
  • A Case Report and Literature Review of Rectosigmoid Crohn’s Disease: A Diagnostic Pitfall Ultimately Leading to Spontaneous Colonic Perforation
    Muhammad Z Ali, Muhammad Usman Tariq, Muhammad Hasan Abid, Hamma Abdulaziz, Mohmmad AlAdwani, Arif Khurshid, Muhammad Rashid, Fawaz Al Thobaiti , Amjad Althagafi
    Cureus.2023;[Epub]     CrossRef
  • Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report
    Guglielmo Albertini Petroni, Laura Francesca Pisani, Edoardo Borsotti, Maria Doria, Maria Laura Annunziata
    SAGE Open Medical Case Reports.2023;[Epub]     CrossRef
  • Thirty-year Trend in Inflammatory Bowel Disease on Jeju Island, South Korea
    Jin Woo Kim, Hyun Joo Song, Sun-Jin Boo, Heung Up Kim, Ki Soo Kang, Soo-Young Na
    The Korean Journal of Gastroenterology.2023; 81(6): 243.     CrossRef
  • PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab
    Min Kyu Kim, Su In Jo, Sang-Yeob Kim, Hyun Lim, Ho Suk Kang, Sung‑Hoon Moon, Byong Duk Ye, Jae Seung Soh, Sung Wook Hwang
    Scientific Reports.2023;[Epub]     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines
    Bing‐He Xiao, Xu‐Dong Ma, Jia‐Jun Lv, Ting Yang, Xin‐Jie Liu, Li‐Ya An, Yu‐Xing Qi, Ming‐Liang Lu, Yong‐Qing Duan, Da‐Li Sun
    International Journal of Clinical Practice.2021;[Epub]     CrossRef
  • Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis
    Yong-Sung Choi, Jong-Kyu Kim, Wan-Jung Kim
    World Journal of Gastrointestinal Endoscopy.2021; 13(9): 407.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
    María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
    Therapeutic Advances in Gastroenterology.2019;[Epub]     CrossRef
  • Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes
    Lukasz S. Wylezinski, Jamieson D. Gray, Julia B. Polk, Andrew J. Harmata, Charles F. Spurlock
    Journal of Clinical Medicine.2019; 8(4): 493.     CrossRef
  • Impact of Cumulative Corticosteroid Dosage on Preventable Hospitalization among Taiwanese Patients with Ankylosing Spondylitis and Inflammatory Bowel Disease
    Beth I. Wallace, Chelsea A. Harris, Lu Wang, Mochuan Liu, Jung-Sheng Chen, Chang-Fu Kuo, Kevin C. Chung
    Journal of Clinical Medicine.2019; 8(5): 614.     CrossRef
  • Perforated diverticulitis in the setting of ulcerative colitis: An unusual case report
    M. Baimas-George, L. Cetrulo, A. Kao, K.R. Kasten
    International Journal of Surgery Case Reports.2018; 49: 126.     CrossRef
  • Assessment of factors associated with smoking cessation at diagnosis or during follow‐up of Crohn's disease
    Eun Mi Song, Gwang‐Un Kim, Myeongsook Seo, Sung Wook Hwang, Sang Hyoung Park, Eunja Kwon, Ho‐Su Lee, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
    Journal of Gastroenterology and Hepatology.2018; 33(1): 180.     CrossRef
  • Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011–2014: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Won Ho Kim, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2017; 62(8): 2102.     CrossRef
  • Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease
    Amanda D. Williams, Olga Y. Korolkova, Amos M. Sakwe, Timothy M. Geiger, Samuel D. James, Roberta L. Muldoon, Alan J. Herline, J. Shawn Goodwin, Michael G. Izban, Mary K. Washington, Duane T. Smoot, Billy R. Ballard, Maria Gazouli, Amosy E. M'Koma, Shree
    PLOS ONE.2017; 12(8): e0179710.     CrossRef
  • Clinical course of ulcerative colitis patients who develop acute pancreatitis
    Jong Wook Kim, Sung Wook Hwang, Sang Hyoung Park, Tae Jun Song, Myung-Hwan Kim, Ho-Su Lee, Byong Duk Ye, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    World Journal of Gastroenterology.2017; 23(19): 3505.     CrossRef
  • Overall and cause‐specific mortality in Korean patients with inflammatory bowel disease: A hospital‐based cohort study
    Ho‐Su Lee, Jaewon Choe, Seon‐Ok Kim, Sun‐Ho Lee, Hyo Jeong Lee, Hyungil Seo, Gwang‐Un Kim, Myeongsook Seo, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Yong Sik Yoon, Chang S
    Journal of Gastroenterology and Hepatology.2017; 32(4): 782.     CrossRef
  • Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease
    Ji Min Lee, Kang-Moon Lee
    Clinical Endoscopy.2016; 49(4): 370.     CrossRef
  • 5,880 View
  • 75 Download
  • 21 Web of Science
  • 20 Crossref
Close layer
A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease
Chun-Chi Lin, Shu-Chen Wei, Been-Ren Lin, Wen-Sy Tsai, Jinn-Shiun Chen, Tzu-Chi Hsu, Wei-Chen Lin, Tien-Yu Huang, Te-Hsin Chao, Hung-Hsin Lin, Jau-Min Wong, Jen-Kou Lin
Intest Res 2016;14(3):248-257.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.248
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

With the recent progress in medical treatment, surgery still plays a necessary and important role in treating ulcerative colitis (UC) patients. In this study, we analyzed the surgical results and outcomes of UC in Taiwan in the recent 20 years, via a multi-center study through the collaboration of Taiwan Society of IBD.

Methods

A retrospective analysis of surgery data of UC patients from January 1, 1995, through December 31, 2014, in 6 Taiwan major medical centers was conducted. The patients' demographic data, indications for surgery, and outcome details were recorded and analyzed.

Results

The data of 87 UC patients who received surgical treatment were recorded. The median post-operative follow-up duration was 51.1 months and ranged from 0.4 to 300 months. The mean age at UC diagnosis was 45.3±16.0 years and that at operation was 48.5±15.2 years. The 3 leading indications for surgical intervention were uncontrolled bleeding (16.1%), perforation (13.8%), and intractability (12.6%). In total, 27.6% of surgeries were performed in an emergency setting. Total or subtotal colectomy with rectal preservation (41.4%) was the most common operation. There were 6 mortalities, all due to sepsis. Emergency operation and low pre-operative albumin level were significantly associated with poor survival (P=0.013 and 0.034, respectively).

Conclusions

In the past 20 years, there was no significant change in the indications for surgery in UC patients. Emergency surgeries and low pre-operative albumin level were associated with poor survival. Therefore, an optimal timing of elective surgery for people with poorly controlled UC is paramount.

Citations

Citations to this article as recorded by  
  • Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023
    Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin
    Intestinal Research.2024; 22(3): 213.     CrossRef
  • Minimally Invasive Surgical Approach to Toxic Colitis
    Zhobin Moghadamyeghaneh, Murwarid Rahimi, Katherine Kopatsis, Anthony Paul Kopatsis, Anthony Kopatsis
    The American Surgeon.2022; 88(7): 1411.     CrossRef
  • Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis
    Yuan-Fang Zhou, Ning Sun, Shi-Rui Cheng, Xiao-Dong Deng, Xiang-Yin Ye, Zheng-Jie Li, Jun Zhou, Gui-Xing Xu, Yu-Zhu Qu, Liu-Yang Huang, Rui-Rui Sun, Fan-Rong Liang
    BMJ Open.2021; 11(8): e045090.     CrossRef
  • Recent Advance in the Management of Dysplasia in the Ulcerative Colitis
    Dong-Hoon Yang
    Journal of Digestive Cancer Reports.2021; 9(2): 50.     CrossRef
  • Trends and risk factors of mortality analysis in patients with inflammatory bowel disease: a Taiwanese nationwide population-based study
    Wei-Chen Lin, Meng-Tzu Weng, Chien-Chih Tung, Yuan-Ting Chang, Yew-Loong Leong, Yu-Ting Wang, Horng-Yuan Wang, Jau-Min Wong, Shu-Chen Wei
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • Variant Two-Stage Ileal Pouch-Anal Anastomosis: An Innovative and Effective Alternative to Standard Resection in Ulcerative Colitis
    Jennifer Samples, Krista Evans, Nicole Chaumont, Paula Strassle, Timothy Sadiq, Mark Koruda
    Journal of the American College of Surgeons.2017; 224(4): 557.     CrossRef
  • 5,565 View
  • 50 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Quality of care in inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul
Hye Kyung Song, Kang-Moon Lee, Sung-Ae Jung, Sung Noh Hong, Dong Soo Han, Suk-Kyun Yang
Intest Res 2016;14(3):240-247.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.240
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The quality of care in inflammatory bowel disease (IBD) has not been systematically estimated. The aim of this study was to investigate the current status of quality of IBD care in Asian countries.

Methods

A questionnaire-based survey was conducted between March 2014 and May 2014. The questionnaire was adopted from "An adult inflammatory bowel disease physician performance measure set" developed by the American Gastroenterological Association. If the respondent executed the performance measure in more than 70% of patients, the measure was regarded as well performed.

Results

A total of 353 medical doctors from Asia completed the survey (116 from Korea, 114 from China, 88 from Japan, 17 from Taiwan, 8 from Hong-Kong, 4 from India, 3 from Singapore, and 1 each from the Philippines, Malaysia and Indonesia). The delivery of performance measures, however, varied among countries. The documentation of IBD and tuberculosis screening before anti-tumor necrosis factor therapy were consistently performed well, while pneumococcal immunization and prophylaxis of venous thromboembolisms in hospitalized patients were performed less frequently in all countries. Physician awareness was positively associated with the delivery of performance measures. Variations were also noted in reasons for non-performance or low performance of quality measures, and the two primary reasons cited were consideration of the measure to be unimportant and lack of time.

Conclusions

The delivery of performance measures varies among physicians in Asian countries, and reflects variations in the quality of care among the countries. This variation should be recognized to improve the quality of care in Asian countries.

Citations

Citations to this article as recorded by  
  • Incidence of Venous Thromboembolism in Asian Patients With Inflammatory Bowel Disease: A Systematic Review and Meta‐Analysis
    Joo Hye Song, Sung Ryul Shim, Dae Sung Kim, Hoon Sup Koo, Kyu Chan Huh
    Journal of Gastroenterology and Hepatology.2025; 40(4): 774.     CrossRef
  • The Incidence and Predictive Factors of Thromboembolism During Hospitalizations for Inflammatory Bowel Disease Flare‐Ups: A Retrospective Cohort Study in Taiwan
    Ming‐Jung Meng, Chen‐Shuan Chung, Chen‐Wang Chang, Yu‐Bin Pan, Chia‐Jung Kuo, Cheng‐Tang Chiu, Puo‐Hsien Le
    Journal of Evaluation in Clinical Practice.2024;[Epub]     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
    Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
    Gut and Liver.2022; 16(4): 555.     CrossRef
  • Risk of venous thromboembolism in Asian patients with inflammatory bowel disease: a nationwide cohort study
    Chan Mi Heo, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Mi Yang, Seonwoo Kim, Young-Ho Kim
    Scientific Reports.2021;[Epub]     CrossRef
  • Incidence and risk factors for venous thrombosis among patients with inflammatory bowel disease in China: a multicenter retrospective study
    Jing Liu, Xiang Gao, Ye Chen, Qiao Mei, Liangru Zhu, Jiaming Qian, Pinjin Hu, Qian Cao
    Intestinal Research.2021; 19(3): 313.     CrossRef
  • Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease
    Yunho Jung
    The Korean Journal of Gastroenterology.2020; 75(1): 1.     CrossRef
  • Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia
    Rupa Banerjee, Partha Pal, Joyce Wing Yan Mak, Siew C Ng
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1076.     CrossRef
  • Quality of care in inflammatory bowel disease: actual health service experiences fall short of the standards
    Antonina Mikocka‐Walus, Wayne Massuger, Simon R. Knowles, Gregory T. Moore, Stephanie Buckton, William Connell, Paul Pavli, Leanne Raven, Jane M. Andrews
    Internal Medicine Journal.2020; 50(10): 1216.     CrossRef
  • Improving the quality of care for inflammatory bowel disease
    Byong Duk Ye, Simon Travis
    Intestinal Research.2019; 17(1): 45.     CrossRef
  • Should Asian inflammatory bowel disease patients need routine thromboprophylaxis?
    Meng-Tzu Weng, Chien-Chih Tung, Jau-Min Wong, Shu-Chen Wei
    Intestinal Research.2018; 16(2): 312.     CrossRef
  • Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies
    Lorant Gonczi, Zsuzsanna Kurti, Petra Anna Golovics, Barbara Dorottya Lovasz, Orsolya Menyhart, Anna Seres, Liza Dalma Sumegi, Alexander Gal, Akos Ilias, Papp Janos, Krisztina Barbara Gecse, Talat Bessisow, Waqqas Afif, Alain Bitton, Zsuzsanna Vegh, Peter
    Digestive and Liver Disease.2018; 50(1): 37.     CrossRef
  • Quality indicators in inflammatory bowel disease
    Sameer K. Berry, Gil Y. Melmed
    Intestinal Research.2018; 16(1): 43.     CrossRef
  • Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment
    Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Journal of Gastroenterology and Hepatology.2018; 33(1): 20.     CrossRef
  • Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
    Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Intestinal Research.2018; 16(1): 4.     CrossRef
  • Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study
    Meng-Tzu Weng, Sang Hyoung Park, Katsuyoshi Matsuoka, Chien-Chih Tung, Jae Yong Lee, Chin-Hao Chang, Suk-Kyun Yang, Mamoru Watanabe, Jau-Min Wong, Shu-Chen Wei
    Inflammatory Bowel Diseases.2018; 24(8): 1791.     CrossRef
  • Assessment of factors associated with smoking cessation at diagnosis or during follow‐up of Crohn's disease
    Eun Mi Song, Gwang‐Un Kim, Myeongsook Seo, Sung Wook Hwang, Sang Hyoung Park, Eunja Kwon, Ho‐Su Lee, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
    Journal of Gastroenterology and Hepatology.2018; 33(1): 180.     CrossRef
  • Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
    Matthew Strohl, Lorant Gonczi, Zsuzsanna Kurt, Talat Bessissow, Peter L Lakatos
    World Journal of Gastroenterology.2018; 24(22): 2363.     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • IBD2020 global forum: results of an international patient survey on quality of care
    Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
    Intestinal Research.2018; 16(4): 537.     CrossRef
  • 6,941 View
  • 79 Download
  • 23 Web of Science
  • 22 Crossref
Close layer
Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul
Hiroshi Nakase, Bora Keum, Byoung Duk Ye, Soo Jung Park, Hoon Sup Koo, Chang Soo Eun
Intest Res 2016;14(3):231-239.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.231
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Inflammatory bowel disease (IBD) management guidelines have been released from Western countries, but no adequate data on the application of these guidelines in Asian countries and no surveys on the treatment of IBD in real practice exist. Since there is a growing need for a customized consensus for IBD treatment in Asian countries, Asian Organization of Crohn's and Colitis performed a multinational survey of medical doctors who treat IBD patients in Asian countries.

Methods

A questionnaire was developed between August 2013 and November 2013. It was composed of 4 domains: personal information, IBD diagnosis, IBD treatment, and quality of IBD care. Upon completion of the questionnaire, a web-based survey was conducted between 17 March 2014 and 12 May 2014.

Results

In total, 353 medical doctors treating IBD from ten Asian countries responded to the survey. This survey data suggested a difference in available medical treatments (budesonide, tacrolimus) among Asian countries. Therapeutic strategies regarding refractory IBD (acute severe ulcerative colitis [UC] refractory to intravenous steroids and refractory Crohn's disease [CD]) and active UC were coincident, however, induction therapies for mild to moderate inflammatory small bowel CD are different among Asian countries.

Conclusions

This survey demonstrated that current therapeutic approaches and clinical management of IBD vary among Asian countries. Based on these results and discussions, we hope that optimal management guidelines for Asian IBD patients will be developed.

Citations

Citations to this article as recorded by  
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
    Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
    Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
  • Management and monitoring of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group: Surgical management,
    Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen Calixto Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
    Journal of Gastroenterology and Hepatology.2023; 38(4): 510.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • How have treatment patterns for patients with inflammatory bowel disease changed in Asian countries?
    Jihye Park
    Intestinal Research.2023; 21(3): 275.     CrossRef
  • Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia
    Chenwen Cai, Juntao Lu, Lijie Lai, Dongjuan Song, Jun Shen, Jinlu Tong, Qing Zheng, Kaichun Wu, Jiaming Qian, Zhihua Ran
    Intestinal Research.2022; 20(2): 213.     CrossRef
  • Indications, Postoperative Management, and Long-term Prognosis of Crohn’s Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West
    Jeanine H C Arkenbosch, Joyce W Y Mak, Jacky C L Ho, Evelien M J Beelen, Nicole S Erler, Frank Hoentjen, Alexander G L Bodelier, Gerard Dijkstra, Mariëlle Romberg-Camps, Nanne K H de Boer, Laurents P S Stassen, Andrea E van der Meulen, Rachel West, Oddeke
    Inflammatory Bowel Diseases.2022; 28(Supplement): S16.     CrossRef
  • UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients
    Radha Gadhok, Hannah Gordon, Gregory Sebepos-Rogers, Samantha Baillie, Saniath Akbar, Jane E. Abbott, Emma Michael, Omer F. Ahmad, Ben Cooper, James O. Lindsay
    Digestive Diseases and Sciences.2020; 65(6): 1790.     CrossRef
  • Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease
    Hiroshi Nakase
    Gut and Liver.2020; 14(1): 7.     CrossRef
  • Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study
    Jesus K. Yamamoto-Furusho, Othman Al Harbi, Alessandro Armuzzi, Webber Chan, Enrique Ponce de Leon, Jiaming Qian, Marina Shapina, Murat Toruner, Chia-Hung Tu, Byong Duk Ye, Morgane Guennec, Cecilia Sison, Dirk Demuth, Olga Fadeeva, Qasim M. Rana Khan
    Digestive and Liver Disease.2020; 52(8): 869.     CrossRef
  • CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients
    Yuki Yamamoto, Hiroshi Nakase, Minoru Matsuura, Shihoko Maruyama, Satohiro Masuda
    International Journal of Molecular Sciences.2020; 21(12): 4347.     CrossRef
  • Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
    Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089.     CrossRef
  • Improving the quality of care for inflammatory bowel disease
    Byong Duk Ye, Simon Travis
    Intestinal Research.2019; 17(1): 45.     CrossRef
  • Increased risk of atrial fibrillation in patients with inflammatory bowel disease: A nationwide population-based study
    You-Jung Choi, Eue-Keun Choi, Kyung-Do Han, Jiesuck Park, Inki Moon, Euijae Lee, Won-Seok Choe, So-Ryoung Lee, Myung-Jin Cha, Woo-Hyun Lim, Seil Oh
    World Journal of Gastroenterology.2019; 25(22): 2788.     CrossRef
  • Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
    Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura,
    Intestinal Research.2018; 16(2): 168.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Computed Tomography and Magnetic Resonance Small Bowel Enterography
    Seong Ho Park, Byong Duk Ye, Tae Young Lee, Joel G. Fletcher
    Gastroenterology Clinics of North America.2018; 47(3): 475.     CrossRef
  • Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome
    Takahiko Toyonaga, Taku Kobayashi, Masaru Nakano, Eiko Saito, Satoko Umeda, Shinji Okabayashi, Ryo Ozaki, Toshifumi Hibi, Emiko Mizoguchi
    PLOS ONE.2017; 12(9): e0185131.     CrossRef
  • Peptide Receptor-Targeted Fluorescent Probe: Visualization and Discrimination between Chronic and Acute Ulcerative Colitis
    Meiying Zeng, Andong Shao, Hui Li, Yan Tang, Qiang Li, Zhiqian Guo, Chungen Wu, Yingsheng Cheng, He Tian, Wei-Hong Zhu
    ACS Applied Materials & Interfaces.2017; 9(15): 13029.     CrossRef
  • Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
    Wei-Chen Lin, Jen-Wei Chou, Hsu-Heng Yen, Wen-Hung Hsu, Hung-Hsin Lin, Jen-Kou Lin, Chiao-Hsiung Chuang, Tien-Yu Huang, Horng-Yuan Wang, Shu-Chen Wei, Jau-Min Wong
    Intestinal Research.2017; 15(4): 487.     CrossRef
  • CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry
    In Young Choi, Sang Hyoung Park, Seong Ho Park, Chang Sik Yu, Yong Sik Yoon, Jong Lyul Lee, Byong Duk Ye, Ah Young Kim, Suk-Kyun Yang
    Korean Journal of Radiology.2017; 18(6): 906.     CrossRef
  • Is Adsorptive Granulocyte and Monocyte Apheresis Effective as an Alternative Treatment Option in Patients with Ulcerative Colitis?
    Seong Ran Jeon
    Gut and Liver.2017; 11(2): 171.     CrossRef
  • Cancer Risk in the Early Stages of Inflammatory Bowel Disease in Korean Patients: A Nationwide Population-based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Won Ho Kim, Jae Hee Cheon
    Journal of Crohn's and Colitis.2017; 11(8): 954.     CrossRef
  • Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
    Ji Won Kim
    Intestinal Research.2016; 14(3): 199.     CrossRef
  • 7,273 View
  • 106 Download
  • 25 Web of Science
  • 24 Crossref
Close layer
Diagnosis of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization for Crohn's and Colitis (AOCC) meeting in Seoul
Eun Soo Kim, Minhu Chen, Jun Lee, Chang-Kyun Lee, You Sun Kim
Intest Res 2016;14(3):224-230.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.224
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

As the number of Asian patients with inflammatory bowel disease (IBD) has increased recently, there is a growing need to improve IBD care in this region. This study is aimed at determining how Asian countries are currently dealing with their IBD patients in terms of diagnosis.

Methods

A questionnaire was designed by the organizing committee of Asian Organization for Crohn's and Colitis, for a multinational web-based survey conducted between March 2014 and May 2014.

Results

A total of 353 Asian medical doctors treating IBD patients responded to the survey (114 in China, 88 in Japan, 116 in Korea, and 35 in other Asian countries). Most of the respondents were gastroenterologists working in an academic teaching hospital. While most of the doctors from China, Japan, and Korea use their own national guidelines for IBD diagnosis, those from other Asian countries most commonly adopt the European Crohn's Colitis Organisation's guideline. Japanese doctors seldom adopt the Montreal classification for IBD. The most commonly used activity scoring system for ulcerative colitis is the Mayo score in all countries except China, whereas that for Crohn's disease (CD) is the Crohn's Disease Activity Index. The most available tool for small-bowel evaluation in CD patients differs across countries. Many physicians administer empirical anti-tuberculous medications before the diagnosis of CD.

Conclusions

The results of this survey demonstrate that Asian medical doctors have different diagnostic approaches for IBD. This knowledge would be important in establishing guidelines for improving the care of IBD patients in this region.

Citations

Citations to this article as recorded by  
  • Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Su Bum Park, Kyeong Ok Kim, Hong Sub Lee, Chang Hwan Choi, Shu Chen Wei, Min Hu Chen, Katsuyoshi Matsuoka
    Intestinal Research.2023; 21(3): 363.     CrossRef
  • Diagnosis of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Han Hee Lee, Jae Jun Park, Bo-In Lee, Ida Hilmi, Jose Sollano, Zhi Hua Ran
    Intestinal Research.2023; 21(3): 328.     CrossRef
  • Treatment of inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Eun Mi Song, Soo-Young Na, Sung Noh Hong, Siew Chien Ng, Tadakazu Hisamatsu, Byong Duk Ye
    Intestinal Research.2023; 21(3): 339.     CrossRef
  • Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
    Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
    Intestinal Research.2023; 21(3): 353.     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Citrus aurantium L. and Its Flavonoids Regulate TNBS-Induced Inflammatory Bowel Disease through Anti-Inflammation and Suppressing Isolated Jejunum Contraction
    Wei He, Yongmin Li, Mengyang Liu, Haiyang Yu, Qian Chen, Yue Chen, Jingya Ruan, Zhijuan Ding, Yi Zhang, Tao Wang
    International Journal of Molecular Sciences.2018; 19(10): 3057.     CrossRef
  • FKBP11 protects intestinal epithelial cells against inflammation‑induced apoptosis via the JNK‑caspase pathway in Crohn's disease
    Xiaotong Wang, Xiaopeng Cui, Chuanwu Zhu, Ming Li, Juan Zhao, Zhongyi Shen, Xiaohang Shan, Liang Wang, Han Wu, Yanting Shen, You Ni, Dongmei Zhang, Guoxiong Zhou
    Molecular Medicine Reports.2018;[Epub]     CrossRef
  • Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
    Hyun Jung Lee, Jae Hee Cheon
    Intestinal Research.2017; 15(3): 311.     CrossRef
  • Advances in Methods for Diagnosis of Chronic Mycobacterial Infections of Gastrointestinal Tract
    Vishwa M Katoch
    Journal of Gastrointestinal Infections.2017; 7(1): 26.     CrossRef
  • Advances in Methods for Diagnosis of Chronic Mycobacterial Infections of Gastrointestinal Tract
    Vishwa M Katoch
    Journal of Gastrointestinal Infections.2017; 7(1): 26.     CrossRef
  • Endoscopic Diagnosis and Differentiation of Inflammatory Bowel Disease
    Ji Min Lee, Kang-Moon Lee
    Clinical Endoscopy.2016; 49(4): 370.     CrossRef
  • Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
    Ji Won Kim
    Intestinal Research.2016; 14(3): 199.     CrossRef
  • 5,467 View
  • 57 Download
  • 11 Web of Science
  • 12 Crossref
Close layer
Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries
Shu Chen Wei
Intest Res 2016;14(3):218-223.   Published online June 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.3.218
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The cost of caring for patients with inflammatory bowel disease (IBD) is high. Without government support, the cost burden will unavoidably rest on the patients and their family. However, the government providing full support will place a large financial burden on the health-care systems of a country. The aim of this study is to understand the current status of public medical insurance systems in caring for IBD patients among Asian countries.

Methods

Questionnaires inquiring about the availability of public health systems; medical, diagnostic, and endoscopy costs; and coverage rate of biologics use were designed and sent to IBD experts in each of the Asian countries studied. The results were summarized according to the feedback from the responders.

Results

The public health insurance coverage rate is high in Taiwan, Japan, South Korea, China, Hong Kong, and Singapore; but low in Malaysia and India. This probably affected the use of expensive medications mostly, such as biologics, as we found that the percentage of Crohn's disease (CD) treated with biologics were as high as 30%–40% in Japan, where the government covers all expenses for IBD patients. In India, the percentage maybe as low as 1% for CD patients, most of whom need to pay for the biologics themselves.

Conclusions

There were differences in the public health insurance systems among the Asian countries studied. This reportprovidesthe background information to understand the differences in the treatment of IBD patients among Asian countries.

Citations

Citations to this article as recorded by  
  • Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
    Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
    Intestinal Research.2025; 23(1): 37.     CrossRef
  • Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
    Johannes Hasskamp, Christian Meinhardt, Petrease H Patton, Antje Timmer
    Cochrane Database of Systematic Reviews.2025;[Epub]     CrossRef
  • Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease
    Tsubasa Oike, Naoki Akizue, Yuki Ohta, Hirotaka Koseki, Masaya Saito, Yuya Yokoyama, Yushi Imai, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Sadahisa Ogasawara, Tomoaki Matsumura, Tomoo Nakagawa, Makoto Arai, Tatsuro Katsuno, Yoshihiro Fukuda, Yoshio K
    Arab Journal of Gastroenterology.2024; 25(3): 257.     CrossRef
  • Reflections from Chinese and Japanese Physicians on Medical Disputes
    Hua Xu, Yining Ruan, Taketoshi Okita, Masao Tabata, Yasuhiro Kadooka, Atsushi Asai
    Asian Bioethics Review.2024; 16(4): 683.     CrossRef
  • Study of Inflammatory Bowel Disease in Patients Undergoing Colonoscopy at a Tertiary Center of Nepal
    Kumud Bhattarai, Ajit Khanal, Ramila Shrestha, Mukesh S Paudel
    Cureus.2024;[Epub]     CrossRef
  • The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
    Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
    Biomedicine & Pharmacotherapy.2023; 157: 114081.     CrossRef
  • Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review
    Narges Norouzkhani, Mahbobeh Faramarzi, Sara Ghodousi Moghadam, Mohammad Amin Karimi, Javad Shokri Shirvani, Ali Bahari, Mahdie ShojaeiBaghini, Saeid Eslami, Hamed Tabesh
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • IBD barriers across the continents – East Asia
    Joyce Wing Yan Mak, Agnes Hiu Yan Ho, Siew Chien Ng
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South‐East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease‐Emerging Nations' Consortium
    Rupa Banerjee, Partha Pal, Ida Hilmi, Uday C Ghoshal, Devendra C Desai, Mohammed Masudur Rahman, Usha Dutta, Syed A Mohiuddin, Munnera Al Mohannadi, Mathew Philip, Ganesh N Ramesh, Madunil A Niriella, Arjuna P De Silva, Hithanadura Janaka de Silva, Pises
    Journal of Gastroenterology and Hepatology.2022; 37(6): 1004.     CrossRef
  • Managing pediatric psoriasis: update on treatments and challenges—a review
    A. A. Hebert, J. Browning, P. C. Kwong, A. M. Duarte, H. N. Price, E. Siegfried
    Journal of Dermatological Treatment.2022; 33(5): 2433.     CrossRef
  • Landscape of inflammatory bowel disease in Singapore
    Daren Low, Nidhi Swarup, Toshiyuki Okada, Emiko Mizoguchi
    Intestinal Research.2022; 20(3): 291.     CrossRef
  • Inflammatory bowel disease in India: challenges and opportunities
    Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
    Frontline Gastroenterology.2021; 12(5): 390.     CrossRef
  • Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
    Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
    Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275.     CrossRef
  • Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View
    Marla C Dubinsky, Kenji Watanabe, Pauliina Molander, Laurent Peyrin-Biroulet, Michele Rubin, Gil Y Melmed, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Susan Connor
    Inflammatory Bowel Diseases.2021; 27(11): 1747.     CrossRef
  • Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou, Yanan Sheng, Haijing Guan
    Advances in Therapy.2021; 38(8): 4233.     CrossRef
  • Impact of Demographic, Clinical and Psychosocial Variables on Drug Adherence and Outcomes in Indian Patients With Inflammatory Bowel Disease
    Rupa Banerjee, Partha Pal, Bhargavi Adigopula, Duvvuru Nageshwar Reddy
    Journal of Clinical Gastroenterology.2021; 55(10): e92.     CrossRef
  • Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance
    Tina Aswani-Omprakash, Vishal Sharma, Shrinivas Bishu, Madhura Balasubramaniam, Sumit Bhatia, Neilanjan Nandi, Neha D Shah, Parakkal Deepak, Shaji Sebastian
    The Lancet Gastroenterology & Hepatology.2021; 6(11): 884.     CrossRef
  • Incidence and Outcomes of Perianal Disease in an Asian Population with Crohn’s Disease: A Nationwide Population-Based Study
    Eun Mi Song, Ho-Su Lee, Ye-Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Jong Lyul Lee, Yong Sik Yoon, Chang Sik Yu, Suk-Kyun Yang
    Digestive Diseases and Sciences.2020; 65(4): 1189.     CrossRef
  • Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
    Digestive Diseases and Sciences.2020; 65(5): 1436.     CrossRef
  • Review of the epidemiology and burden of ulcerative colitis in Latin America
    Paulo Gustavo Kotze, Flavio Steinwurz, Carlos Francisconi, Cyrla Zaltman, Marcia Pinheiro, Leonardo Salese, Dario Ponce de Leon
    Therapeutic Advances in Gastroenterology.2020;[Epub]     CrossRef
  • Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
    Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
    The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089.     CrossRef
  • Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study
    Hsu-Heng Yen, Meng-Tzu Weng, Chien-Chih Tung, Yu-Ting Wang, Yuan Ting Chang, Chin-Hao Chang, Ming-Jium Shieh, Jau-Min Wong, Shu-Chen Wei
    Intestinal Research.2019; 17(1): 54.     CrossRef
  • Incidence and clinical impact of perianal disease in patients with ulcerative colitis: A nationwide population‐based study
    Eun Mi Song, Ho‐Su Lee, Ye‐Jee Kim, Eun Hye Oh, Nam Seok Ham, Jeongseok Kim, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang
    Journal of Gastroenterology and Hepatology.2019; 34(6): 1011.     CrossRef
  • Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China
    Sanskriti Varma, Jun Hu, Ambar Mehta, Yiran Song, Angela Park, Min Zhi, Susan Hutfless
    JGH Open.2019; 3(3): 234.     CrossRef
  • Regaining normality: A grounded theory study of the illness experiences of Chinese patients living with Crohn’s disease
    Jiayin Ruan, Yunxian Zhou
    International Journal of Nursing Studies.2019; 93: 87.     CrossRef
  • Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
    Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
    Journal of Gastroenterology and Hepatology.2019; 34(8): 1296.     CrossRef
  • Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
    Choon Jin Ooi, Ida Hilmi, Rupa Banerjee, Sai Wei Chuah, Siew Chien Ng, Shu Chen Wei, Govind K Makharia, Pises Pisespongsa, Min Hu Chen, Zhi Hua Ran, Byong Duk Ye, Dong Il Park, Khoon Lin Ling, David Ong, Vineet Ahuja, Khean Lee Goh, Jose Sollano, Wee Chia
    Intestinal Research.2019; 17(3): 285.     CrossRef
  • Stopping anti‐tumour necrosis factor therapy in patients with perianal Crohn’s disease
    Joyce Wing Yan Mak, Whitney Tang, Terry Cheuk Fung Yip, Zhi Hua Ran, Shu Chen Wei, Vineet Ahuja, Sudheer Kumar, Wai Keung Leung, Ida Hilmi, Julajak Limsrivilai, Satimai Aniwan, Belsy C. Y. Lam, Kam Hon Chan, Ka Man Ng, Chi Man Leung, Michael K. K. Li, Fu
    Alimentary Pharmacology & Therapeutics.2019; 50(11-12): 1195.     CrossRef
  • Increased Risk of Herpes Zoster Infection in Patients With Inflammatory Bowel Diseases in Korea
    Kiju Chang, Ho-Su Lee, Ye-Jee Kim, Seon-Ok Kim, Sung-Han Kim, Sun-Ho Lee, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Clinical Gastroenterology and Hepatology.2018; 16(12): 1928.     CrossRef
  • An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative Colitis
    Ho-Su Lee, Suk-Kyun Yang, Myunghee Hong, Seulgi Jung, Byoung Mok Kim, Jung Won Moon, Sang Hyoung Park, Byong Duk Ye, Seak Hee Oh, Kyung Mo Kim, Yong Sik Yoon, Chang Sik Yu, Jiwon Baek, Cue Hyunkyu Lee, Buhm Han, Jianjun Liu, Talin Haritunians, Dermot P B
    Journal of Crohn's and Colitis.2018;[Epub]     CrossRef
  • Paradigm Shift of Healthcare Cost for Patients with Inflammatory Bowel Diseases: A Claims Data-Based Analysis in Japan
    Shota Saito, Kyoko Nakazawa, Kenji Suzuki, Takashi Ishikawa, Kouhei Akazawa
    Gastrointestinal Disorders.2018; 1(1): 120.     CrossRef
  • Overall and cause‐specific mortality in Korean patients with inflammatory bowel disease: A hospital‐based cohort study
    Ho‐Su Lee, Jaewon Choe, Seon‐Ok Kim, Sun‐Ho Lee, Hyo Jeong Lee, Hyungil Seo, Gwang‐Un Kim, Myeongsook Seo, Eun Mi Song, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Kyung‐Jo Kim, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Yong Sik Yoon, Chang S
    Journal of Gastroenterology and Hepatology.2017; 32(4): 782.     CrossRef
  • Emerging biologics in inflammatory bowel disease
    Heyson Chi-hey Chan, Siew Chien Ng
    Journal of Gastroenterology.2017; 52(2): 141.     CrossRef
  • Balloon-Assisted Enteroscopy and Capsule Endoscopy in Suspected Small Bowel Crohn’s Disease
    Hsu-Heng Yen, Chen-Wang Chang, Jen-Wei Chou, Shu-Chen Wei
    Clinical Endoscopy.2017; 50(5): 417.     CrossRef
  • Pivot to Asia: inflammatory bowel disease burden
    Prashant Singh, Ashwin Ananthakrishnan, Vineet Ahuja
    Intestinal Research.2017; 15(1): 138.     CrossRef
  • Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience
    Tarun Rai, Bikash Narayan Choudhury, Saurabh Kedia, Sawan Bopanna, Pratap Mouli Venigalla, Sushil Kumar Garg, Vikas Singla, Govind Makharia, Vineet Ahuja
    Digestive Diseases and Sciences.2017; 62(4): 1025.     CrossRef
  • Results of the first survey for the current status of inflammatory bowel disease management in Asian countries
    Ji Won Kim
    Intestinal Research.2016; 14(3): 199.     CrossRef
  • 18,511 View
  • 79 Download
  • 36 Web of Science
  • 37 Crossref
Close layer
Comparison of the efficacy of disinfectants in automated endoscope reprocessors for colonoscopes: tertiary amine compound (Sencron2®) versus ortho-phthalaldehyde (Cidex®OPA)
Hyun Il Seo, Dae Sung Lee, Eun Mi Yoon, Min-Jung Kwon, Hyosoon Park, Yoon Suk Jung, Jung Ho Park, Chong Il Sohn, Dong Il Park
Intest Res 2016;14(2):178-182.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.178
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To prevent the transmission of pathogens by endoscopes, following established reprocessing guidelines is critical. An ideal reprocessing step is simple, fast, and inexpensive. Here, we evaluated and compared the efficacy and safety of two disinfectants, a tertiary amine compound (TAC) and ortho-phthalaldehyde (OPA).

Methods

A total of 100 colonoscopes were randomly reprocessed using two same automated endoscope reprocessors, according to disinfectant. The exposure time was 10 minutes for 0.55% OPA (Cidex® OPA, Johnson & Johnson) and 5 minutes for 4% TAC (Sencron2®, Bab Gencel Pharma & Chemical Ind. Co.). Three culture samples were obtained from each colonoscope after reprocessing.

Results

A total of nine samples were positive among the 300 culture samples. The positive culture rate was not statistically different between the two groups (4% for OPA and 2% for TAC, P=0.501). There were no incidents related to safety during the study period.

Conclusions

TAC was non-inferior in terms of reprocessing efficacy to OPA and was safe to use. Therefore, TAC seems to be a good alternative disinfectant with a relatively short exposure time and is also less expensive than OPA.

Citations

Citations to this article as recorded by  
  • What doesn’t kill biofilm, makes them stronger: critical methodological considerations for endoscope reprocessing
    R. Kanaujia, A. Sharma, M. Biswal, V. Singh
    Journal of Hospital Infection.2025; 156: 135.     CrossRef
  • Synthesis, Characterization and Investigation of Antimicrobial Activity of Orthophtaldehyde Nanoflowers
    Gülten CAN SEZGİN, Nilay ILDİZ
    Middle Black Sea Journal of Health Science.2023; 9(2): 245.     CrossRef
  • A Manufacturer and User Facility Device Experience Analysis of Upper Aerodigestive Endoscopy Contamination: Is Flexible Laryngoscopy Different?
    Roy Jiang, David A. Kasle, Faisal Alzahrani, Nikita Kohli, Michael Z. Lerner
    The Laryngoscope.2021; 131(3): 598.     CrossRef
  • Electrochemical and Spectrometric Study of Reactivity of Orthophthalaldehyde with Hydroxylamine: Mechanistic Considerations
    Joël Donkeng‐Dazie, Jiří Urban, Jiří Ludvík
    ChemistrySelect.2021; 6(20): 4881.     CrossRef
  • Reactivity of orthophthalaldehyde with aliphatic, alicyclic and aromatic primary diamines: Electrochemical study and mechanistic considerations
    Joël Donkeng Dazie, Alan Liška, Jiří Urban, Jiří Ludvík
    Journal of Electroanalytical Chemistry.2018; 821: 131.     CrossRef
  • Efficacy of Peracetic Acid (EndoPA®) for Disinfection of Endoscopes
    Ji Min Lee, Kang-Moon Lee, Dae Bum Kim, Se Eun Go, Sungwoo Ko, Yoongoo Kang, Solim Hong
    The Korean Journal of Gastroenterology.2018; 71(6): 319.     CrossRef
  • Planarity of substituted pyrrole and furan rings in (3R*, 1′S*, 3′R*)-3-(1′-tert-butylamino-1′H, 3′ H-benzo[c]furan-3′-yl)-2-tert-butyl-2,3-dihydro-1H-benzo[c]pyrrol-1-one
    Joel Donkeng Dazie, Alan Liška, Jiří Ludvík, Jan Fábry, Michal Dušek, Václav Eigner
    Zeitschrift für Kristallographie - Crystalline Materials.2017; 232(6): 441.     CrossRef
  • 7,417 View
  • 53 Download
  • 4 Web of Science
  • 7 Crossref
Close layer
Do we need colonoscopy verification in patients with fundic gland polyp?
Hee Sook Lee, Younjeong Choi, Ja Young Jung, Young-Jun Sung, Dong Won Ahn, Ji Bong Jeong, Byeong Gwan Kim, Kook Lae Lee, Seong-Joon Koh, Ji Won Kim
Intest Res 2016;14(2):172-177.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.172
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The aim of this study was to evaluate the prevalence of colorectal neoplasia in subjects with fundic gland polyps (FGPs) and the relationship between FGPs and colorectal neoplasia in Korea.

Methods

We analyzed 128 consecutive patients with FPGs who underwent colonoscopy between January 2009 and December 2013. For each case, age- (±5 years) and sex-matched controls were identified from among patients with hyperplastic polyps, gastric neoplasms, and healthy controls. Clinical characteristics were reviewed from medical records, colonoscopic findings, pathologic findings, and computed tomography images. The outcome was evaluated by comparison of advanced colonic neoplasia detection rates.

Results

Of the 128 patients, seven (5.1%) had colon cancers and seven (5.1%) had advanced adenomas. A case-control study revealed that the odds of detecting a colorectal cancer was 3.8 times greater in patients with FGPs than in the age- and sex-matched healthy controls (odds ratio [OR], 3.80; 95% confidence interval [CI], 1.09–13.24; P =0.04) and 4.1 times greater in patients with FGPs than in healthy controls over 50 years of age (OR, 4.10; 95% CI, 1.16–14.45; P =0.04). Among patients with FGPs over 50 years old, male sex (OR, 4.83; 95% CI, 1.23–18.94; P =0.02), and age (OR, 9.90; 95% CI, 1.21–81.08; P =0.03) were associated with an increased prevalence of advanced colorectal neoplasms.

Conclusions

The yield of colonoscopy in colorectal cancer patients with FGPs was substantially higher than that in average-risk subjects. Colonoscopy verification is warranted in patients with FGPs, especially in those 50 years of age or older.

Citations

Citations to this article as recorded by  
  • Current Guidelines and Advances in the Management of Fundic Gland Polyps
    Majed Ali, Lynn Srour, Mustapha Bitar, Karam Karam, Ihab I. El Hajj, Elias Fiani
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1374.     CrossRef
  • Cold snare polypectomy for fundic gland polyps
    Chi‐Hung Chen, Jen‐Chieh Huang, Jeng‐Shiann Shin
    Advances in Digestive Medicine.2022; 9(1): 17.     CrossRef
  • Clinical features of fundic gland polyps and their correlation with colorectal tumors
    Xue-Mei Yang, Hong Xu
    World Chinese Journal of Digestology.2020; 28(20): 1036.     CrossRef
  • Parietalzellhypertrophie und Drüsenkörperzysten
    M. Venerito, A. Canbay, M. Vieth
    Der Gastroenterologe.2018; 13(2): 90.     CrossRef
  • 7,111 View
  • 43 Download
  • 5 Web of Science
  • 4 Crossref
Close layer
Usefulness of endoscopic resection using the band ligation method for rectal neuroendocrine tumors
Ju Seung Kim, Yoon Jae Kim, Jun-Won Chung, Jung Ho Kim, Kyoung Oh Kim, Kwang An Kwon, Dong Kyun Park, Jung Suk An
Intest Res 2016;14(2):164-171.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.164
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Rectal neuroendocrine tumors (NETs) are among the most common of gastrointestinal NETs. Due to recent advances in endoscopy, various methods of complete endoscopic resection have been introduced for small (≤10 mm) rectal NETs. However, there is a debate about the optimal treatment for rectal NETs. In our study, we aimed to evaluate the efficacy and feasibility of endoscopic resection using pneumoband and elastic band (ER-BL) for rectal NETs smaller than 10 mm in diameter.

Methods

A total of 55 patients who were diagnosed with rectal NET from January 2004 to December 2011 at Gil Medical Center were analyzed retrospectively. Sixteen patients underwent ER-BL. For comparison, 39 patients underwent conventional endoscopic mucosal resection (EMR).

Results

There was a markedly lower deep margin positive rate for ER-BL than for conventional EMR (6% [1/16] vs. 46% [18/39], P=0.029). Four patients who underwent conventional EMR experienced perforation or bleeding. However, they recovered within a few days. On the other hand, patients whounderwent endoscopic resection using a pneumoband did not experience any complications. In multivariate analysis, ER-BL (P=0.021) was independently associated with complete resection.

Conclusions

ER-BL is an effective endoscopic treatment with regards to deep margin resection for rectal NET smaller than 10 mm.

Citations

Citations to this article as recorded by  
  • Risk factors for residual tumors in histologically incompletely resected rectal neuroendocrine tumors
    Jung-Bin Park, Ga Hee Kim, Minjun Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Seok-Byung Lim, Seung-Mo Hong, Dong-Hoon Yang
    Digestive and Liver Disease.2025; 57(7): 1473.     CrossRef
  • Current status of endoscopic resection for small rectal neuroendocrine tumors
    Jian-Ning Liu, Hui Chen, Nian Fang
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis
    Jie Chen, Jianfang Ye, Xiong Zheng, Jianyong Chen
    Journal of Gastrointestinal Surgery.2024; 28(3): 301.     CrossRef
  • Endoscopic mucosal resection using anchored snare Tip-in versus precut technique for small rectal neuroendocrine tumors
    Seung Wook Hong, Dong-Hoon Yang, Yoo Jin Lee, Dong Hoon Baek, Jaeyoung Chun, Hyun Gun Kim, Sung Joo Kim, Seung-Mo Hong, Dae-Seong Myung
    The Korean Journal of Internal Medicine.2024; 39(2): 238.     CrossRef
  • Outcome of Endoscopic Resection of Rectal Neuroendocrine Tumors ≤ 10 mm
    Roberta Elisa Rossi, Maria Terrin, Silvia Carrara, Roberta Maselli, Alexia Francesca Bertuzzi, Silvia Uccella, Andrea Gerardo Antonio Lania, Alessandro Zerbi, Cesare Hassan, Alessandro Repici
    Diagnostics.2024; 14(14): 1484.     CrossRef
  • Clinical outcomes of endoscopic resection for rectal neuroendocrine tumors: Advantages of endoscopic submucosal resection with a ligation device compared to conventional EMR and ESD
    Yuki Kamigaichi, Ken Yamashita, Shiro Oka, Hirosato Tamari, Yasutsugu Shimohara, Tomoyuki Nishimura, Katsuaki Inagaki, Yuki Okamoto, Hidenori Tanaka, Ryo Yuge, Yuji Urabe, Koji Arihiro, Shinji Tanaka
    DEN Open.2022;[Epub]     CrossRef
  • Endoscopic Mucosal Resection in Children
    David S. Vitale, Kelly Wang, Laith H. Jamil, Kenneth H. Park, Quin Y. Liu
    Journal of Pediatric Gastroenterology and Nutrition.2022; 74(1): 20.     CrossRef
  • Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance
    Camilla Gallo, Roberta Elisa Rossi, Federica Cavalcoli, Federico Barbaro, Ivo Boškoski, Pietro Invernizzi, Sara Massironi
    World Journal of Gastroenterology.2022; 28(11): 1123.     CrossRef
  • Comparison of underwater endoscopic mucosal resection and endoscopic submucosal dissection of rectal neuroendocrine tumors (with videos)
    Sung Sil Park, Kyung Su Han, Bun Kim, Byung Chang Kim, Chang Won Hong, Dae Kyung Sohn, Hee Jin Chang
    Gastrointestinal Endoscopy.2020; 91(5): 1164.     CrossRef
  • Treatment Results of Endoscopic Mucosal Resection with a Ligation Device for Duodenal Neuroendocrine Tumors
    Ai Fujimoto, Motoki Sasaki, Osamu Goto, Tadateru Maehata, Yasutoshi Ochiai, Motohiko Kato, Atsushi Nakayama, Teppei Akimoto, Jyunko Kuramoto, Yuichiro Hayashi, Kaori Kameyama, Naohisa Yahagi
    Internal Medicine.2019; 58(6): 773.     CrossRef
  • Endoscopic submucosal resection with an endoscopic variceal ligation device for the treatment of rectal neuroendocrine tumors
    Masahide Ebi, Shoko Nakagawa, Yoshiharu Yamaguchi, Yasuhiro Tamura, Shinya Izawa, Yasutaka Hijikata, Takaya Shimura, Yasushi Funaki, Naotaka Ogasawara, Makoto Sasaki, Takashi Joh, Kunio Kasugai
    International Journal of Colorectal Disease.2018; 33(12): 1703.     CrossRef
  • Neuroendocrine neoplasms of rectum: A management update
    Emilio Bertani, Davide Ravizza, Massimo Milione, Sara Massironi, Chiara Maria Grana, Dario Zerini, Alessandra Nella Piccioli, Giuseppe Spinoglio, Nicola Fazio
    Cancer Treatment Reviews.2018; 66: 45.     CrossRef
  • 7,032 View
  • 59 Download
  • 14 Web of Science
  • 12 Crossref
Close layer
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson
Intest Res 2016;14(2):152-163.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.152
AbstractAbstract PDFSupplementary MaterialPubReaderePub
<b>Background/Aims</b><br/>

This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).

Methods

Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8–26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.

Results

Mean adalimumab serum concentrations during the induction phase were 13.9–18.1 µg/mL (160/80 mg group) and 7.5−9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.

Conclusions

Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.

Citations

Citations to this article as recorded by  
  • Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn’s disease
    Sisi Zhou, Zeyu Huang, Wenjing Hou, Yiting Lin, Jing Yu
    Inflammation Research.2024; 73(2): 199.     CrossRef
  • Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis
    Brigida Barberio, David J Gracie, Christopher J Black, Alexander C Ford
    Gut.2023; 72(2): 264.     CrossRef
  • Seronegative spondyloarthropathy-associated inflammatory bowel disease
    Chrong-Reen Wang, Hung-Wen Tsai
    World Journal of Gastroenterology.2023; 29(3): 450.     CrossRef
  • Early Change in Fecal Calprotectin Predicts One‐Year Outcome in Children Newly Diagnosed With Ulcerative Colitis
    Chenthan Krishnakumar, Ashwin N. Ananthakrishnan, Brendan M. Boyle, Anne M. Griffiths, Neal S. LeLeiko, David R. Mack, James F. Markowitz, Joel R. Rosh, Cary G. Sauer, Thomas D. Walters, Erin Bonkowski, Lee A. Denson, Jeffrey S. Hyams, Subra Kugathasan
    Journal of Pediatric Gastroenterology and Nutrition.2022; 74(1): 72.     CrossRef
  • Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis
    Gerd R. Burmester, Kenneth B. Gordon, James T. Rosenbaum, Dilek Arikan, Winnie L. Lau, Peigang Li, Freddy Faccin, Remo Panaccione
    Advances in Therapy.2020; 37(1): 364.     CrossRef
  • Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies
    Melissa Joyce Sam, Susan Jane Connor, Watson Wa-Sang Ng, Catherine Mei-Ling Toong
    Therapeutic Drug Monitoring.2020; 42(6): 821.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Updated treatment strategies for intestinal Behçet’s disease
    Yong Eun Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2018; 33(1): 1.     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea
    Hyungil Seo, Byong Duk Ye, Eun Mi Song, Sun-Ho Lee, Kiju Chang, Ho-Su Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
    Digestive Diseases and Sciences.2017; 62(10): 2882.     CrossRef
  • Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study
    Chrong-Reen Wang, Chia-Tse Weng, Chung-Ta Lee, Kuo-Yuan Huang, Sheng-Min Hsu, Ming-Fei Liu
    Scientific Reports.2017;[Epub]     CrossRef
  • 7,372 View
  • 107 Download
  • 11 Web of Science
  • 11 Crossref
Close layer
Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang
Intest Res 2016;14(2):146-151.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.146
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Anti-tumor necrosis factor (TNF) therapy for active ulcerative colitis (UC) and Crohn's disease (CD) is associated with increased risks of tuberculosis (TB) infection. We analyzed the incidence and clinical features of Korean patients with inflammatory bowel disease (IBD) who developed active TB during anti-TNF therapy.

Methods

Ten cases of active TB developed in patients treated with infliximab (n=592) or adalimumab (n=229) for UC (n=160) or CD (n=661) were reviewed. We analyzed demographics, interval between start of anti-TNF therapy and active TB development, tests for latent TB infection (LTBI), concomitant medications, and the details of diagnosis and treatments for TB.

Results

The incidence of active TB was 1.2% (10/821): 1.5% (9/592) and 0.4% (1/229) in patients receiving infliximab and adalimumab, respectively. The median time to the development of active TB after initiation of anti-TNF therapy was three months (range: 2–36). Three patients had past histories of treatment for TB. Positive findings in a TB skin test (TST) and/or interferon gamma releasing assay (IGRA) were observed in three patients, and two of them received anti-TB prophylaxis. Two patients were negative by both TST and IGRA. The most common site of active TB was the lungs, and the active TB was cured in all patients.

Conclusions

Active TB can develop during anti-TNF therapy in IBD patients without LTBI, and even in those with histories of TB treatment or LTBI prophylaxis. Physicians should be aware of the potential for TB development during anti-TNF therapy, especially in countries with a high prevalence of TB.

Citations

Citations to this article as recorded by  
  • (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review
    Thomas Theo Brehm, Maja Reimann, Niklas Köhler, Christoph Lange
    Clinical Microbiology and Infection.2024; 30(8): 989.     CrossRef
  • Real-world effectiveness of ustekinumab in maintenance therapy for Crohn´s disease
    O.V. Knyazev, O.B. Schukina, A.V. Kagramanova, A.A. Lishchinskaya, I.A. Li, E.A. Sabelnikova, B.A. Nanaeva, M.Yu. Timanovskaya, T.A. Kosacheva, N.A. Fadeeva, K.A. Nikolskaya, E.Yu. Zhulina, N.V. Kamzarakova, A.I. Parfenov
    Russian Journal of Evidence-Based Gastroenterology.2023; 12(3): 29.     CrossRef
  • Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial
    William J. Sandborn, Rory Rebuck, Yuhua Wang, Bin Zou, Omoniyi J. Adedokun, Christopher Gasink, Bruce E. Sands, Stephen B. Hanauer, Stephan Targan, Subrata Ghosh, Willem J.S. de Villiers, Jean-Frederic Colombel, Brian G. Feagan, John P. Lynch
    Clinical Gastroenterology and Hepatology.2022; 20(3): 578.     CrossRef
  • Monitoring frequency of interferon gamma release assay for tuberculosis surveillance following infliximab therapy in patients with Crohn's disease
    Qin Yu Yang, Yi Juan Liu, Ye Xu, Lin Zhang, Cheng Dang Wang
    Journal of Digestive Diseases.2021; 22(8): 473.     CrossRef
  • Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy
    Jihye Kim, Jong Pil Im, Jae-Joon Yim, Chang Kyun Lee, Dong Il Park, Chang Soo Eun, Sung-Ae Jung, Jeong Eun Shin, Kang-Moon Lee, Jae Hee Cheon
    The Korean Journal of Gastroenterology.2020; 75(1): 29.     CrossRef
  • Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
    Hosim Soh, Jaeyoung Chun, Kyungdo Han, Seona Park, Gukhwan Choi, Jihye Kim, Jooyoung Lee, Jong Pil Im, Joo Sung Kim
    Gut and Liver.2019; 13(3): 333.     CrossRef
  • Discontinuation of Biological Treatments in Inflammatory Bowel Disease
    Shomron Ben-Horin, Ren Mao, Yun Qiu, Minhu Chen
    Journal of Clinical Gastroenterology.2018; 52(1): 6.     CrossRef
  • Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
    Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Intestinal Research.2018; 16(1): 17.     CrossRef
  • Novel treatments for inflammatory bowel disease
    Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
    The Korean Journal of Internal Medicine.2018; 33(1): 20.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 2: Management
    Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasu
    Journal of Gastroenterology and Hepatology.2018; 33(1): 30.     CrossRef
  • Changing treatment paradigms for the management of inflammatory bowel disease
    Jong Pil Im, Byong Duk Ye, You Sun Kim, Joo Sung Kim
    The Korean Journal of Internal Medicine.2018; 33(1): 28.     CrossRef
  • Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
    Jieun Kang, Dae Hyun Jeong, Minkyu Han, Suk-Kyun Yang, Jeong-Sik Byeon, Byong Duk Ye, Sang Hyoung Park, Sung Wook Hwang, Tae Sun Shim, Kyung-Wook Jo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • CD8 + CD28 + /CD8 + CD28 − T cell equilibrium can predict the active stage for patients with inflammatory bowel disease
    Shi-xue Dai, Hong-xiang Gu, Qian-yi Lin, Shao-zhuo Huang, Tiao-si Xing, Qing-fang Zhang, Gang Wu, Min-hua Chen, Wan-er Tan, Hong-jian Jian, Zhong-wen Zheng, Tao Zhong, Min-hai Zhang, Xing-fang Cheng, Peng Huang, Guang-jie Liao, Wei-hong Sha
    Clinics and Research in Hepatology and Gastroenterology.2017; 41(6): 693.     CrossRef
  • 6,058 View
  • 72 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
Shunsuke Komoto, Satoshi Motoya, Yuji Nishiwaki, Toshiyuki Matsui, Reiko Kunisaki, Katsuyoshi Matsuoka, Naoki Yoshimura, Takashi Kagaya, Makoto Naganuma, Nobuyuki Hida, Mamoru Watanabe, Toshifumi Hibi, Yasuo Suzuki, Soichiro Miura, Ryota Hokari
Intest Res 2016;14(2):139-145.   Published online April 27, 2016
DOI: https://doi.org/10.5217/ir.2016.14.2.139
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines.

Methods

This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines.

Results

Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037).

Conclusions

Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

Citations

Citations to this article as recorded by  
  • Ulcerative Colitis in Pregnancy: A Japanese Multicenter Cohort Study Focusing on Their Mutual Influence
    Yuichi Shimodate, Akiko Shiotani, Ken-ichi Tarumi, Hiroshi Matsumoto, Osamu Handa, Noriaki Tomioka, Naoyuki Nishimura, Kazuhiro Matsueda, Hirokazu Mouri, Motowo Mizuno
    Internal Medicine.2025; 64(11): 1633.     CrossRef
  • North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
    Raed Alhusayen, Serena Dienes, Megan Lam, Afsaneh Alavi, Ali Alikhan, Maria Aleshin, Emad Bahashwan, Steve Daveluy, Noah Goldfarb, Amit Garg, Wayne Gulliver, Tarannum Jaleel, Alexa B. Kimball, Mark G. Kirchhof, Joslyn Kirby, Joi Lenczowski, Hadar Lev-Tov,
    Journal of the American Academy of Dermatology.2025; 92(4): 825.     CrossRef
  • A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
    Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
    Revista Colombiana de Reumatología.2024; 31(3): 290.     CrossRef
  • Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review
    Wei Huang, Xinxing Zhang, Li Zhang, Xiaosong Dai, Heping Chen, Qin Xie
    BMC Pregnancy and Childbirth.2024;[Epub]     CrossRef
  • A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
    Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
    Revista Colombiana de Reumatología (English Edition).2024; 31(3): 290.     CrossRef
  • The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
    Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
    Biomedicine & Pharmacotherapy.2023; 157: 114081.     CrossRef
  • Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy
    Nahla A. Azzam, Abdulelah Almutairdi, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baw
    Saudi Journal of Gastroenterology.2023;[Epub]     CrossRef
  • Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis
    Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
    Clinical Gastroenterology and Hepatology.2022; 20(1): 74.     CrossRef
  • British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
    Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Se
    Rheumatology.2022;[Epub]     CrossRef
  • Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
    Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
    Current Pharmaceutical Design.2021; 27(19): 2317.     CrossRef
  • Exposure to Infliximab During Pregnancy: Post-Marketing Experience
    Anja Geldhof, Jennifer Slater, Michael Clark, Urmila Chandran, Danielle Coppola
    Drug Safety.2020; 43(2): 147.     CrossRef
  • The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
    Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
    The Korean Journal of Internal Medicine.2020; 35(1): 41.     CrossRef
  • The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
    Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
    Journal of Rheumatic Diseases.2020; 27(1): 4.     CrossRef
  • Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies
    Nicole W Tsao, Nevena Rebic, Larry D Lynd, Mary A De Vera
    Rheumatology.2020; 59(8): 1808.     CrossRef
  • Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
    N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
    Drugs.2020; 80(16): 1699.     CrossRef
  • Pregnancy and Neuromyelitis Optica Spectrum Disorder – Reciprocal Effects and Practical Recommendations: A Systematic Review
    Rohan D'Souza, Danielle Wuebbolt, Katarina Andrejevic, Rizwana Ashraf, Vanessa Nguyen, Nusrat Zaffar, Dalia Rotstein, Ahraaz Wyne
    Frontiers in Neurology.2020;[Epub]     CrossRef
  • Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: A Retrospective Evaluation
    Ayumi Ito, Bunei Iizuka, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
    Internal Medicine.2018; 57(2): 159.     CrossRef
  • The use of biologics and small molecules in pregnant patients with rheumatic diseases
    Maria Gerosa, Lorenza Maria Argolini, Carolina Artusi, Cecilia Beatrice Chighizola
    Expert Review of Clinical Pharmacology.2018; 11(10): 987.     CrossRef
  • Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
    Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280.     CrossRef
  • Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis
    Begoña Gonzalez-Suarez, Shreyashee Sengupta, Alan C Moss
    World Journal of Gastroenterology.2017; 23(45): 8082.     CrossRef
  • Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
    Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
    Intestinal Research.2017; 15(1): 90.     CrossRef
  • Concerns in pregnancy and childbirth of women with inflammatory bowel disease
    Sung-Ae Jung
    Intestinal Research.2016; 14(2): 107.     CrossRef
  • Common Adverse Effects of Anti-TNF Agents on Gestation
    Zacharias Fasoulakis, Panagiotis Antsaklis, Nikolaos Galanopoulos, Emmanuel Kontomanolis
    Obstetrics and Gynecology International.2016; 2016: 1.     CrossRef
  • 7,336 View
  • 80 Download
  • 25 Web of Science
  • 23 Crossref
Close layer
Spectrum of chronic small bowel diarrhea with malabsorption in Indian subcontinent: is the trend really changing?
Nirav Pipaliya, Meghraj Ingle, Chetan Rathi, Prateik Poddar, Nilesh Pandav, Prabha Sawant
Intest Res 2016;14(1):75-82.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.75
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

This study aimed to document the recent etiological spectrum of chronic diarrhea with malabsorption and also to compare features that differentiate tropical sprue from parasitic infections, the two most common etiologies of malabsorption in the tropics.

Methods

We analyzed 203 consecutive patients with malabsorption. The etiological spectrum and factors that differentiated tropical sprue from parasitic infections were analyzed.

Results

The most common etiology was tropical sprue (n=98, 48.3%) followed by parasitic infections (n=25, 12.3%) and tuberculosis (n=22, 10.8%). Other causes were immunodeficiency (n=15, 7.3%; 12 with human immunodeficiency virus and 3 with hypogammaglobulinemia), celiac disease (n=11, 5.4%), Crohn's disease (n=11, 5.4%), small intestinal bacterial overgrowth (n=11, 5.4%), hyperthyroidism (n=4, 1.9%), diabetic diarrhea (n=4, 1.9%), systemic lupus erythematosus (n=3, 1.4%), metastatic carcinoid (n=1, 0.5%) and Burkitt's lymphoma (n=1, 0.5%). On multivariate analysis, features that best differentiated tropical sprue from parasitic infections were larger stool volume (P=0.009), severe weight loss (P=0.02), knuckle hyperpigmentation (P=0.008), low serum B12 levels (P=0.05), high mean corpuscular volume (P=0.003), reduced height or scalloping of the duodenal folds on endoscopy (P=0.003) and villous atrophy on histology (P=0.04). Presence of upper gastrointestinal (GI) symptoms like bloating, nausea and vomiting predicted parasitic infections (P=0.01).

Conclusions

Tropical sprue and parasitic infections still dominate the spectrum of malabsorption in India. Severe symptoms and florid malabsorption indicate tropical sprue while the presence of upper GI symptoms indicates parasitic infections.

Citations

Citations to this article as recorded by  
  • The etiological profile of chronic organic non-bloody diarrhea in India: Emergence of inflammatory bowel disease as a dominant cause
    Prachi Daga, Amarender Singh Puri, Lipika Lipi, Sumit Bhatia, Randhir Sud
    Indian Journal of Gastroenterology.2025; 44(2): 181.     CrossRef
  • Inflammatory Bowel Disease in Children
    Asha Jois, George Alex
    Indian Journal of Pediatrics.2024; 91(5): 490.     CrossRef
  • The etiological profile of chronic organic non-bloody diarrhea in India: A closer look
    Uday C. Ghoshal, Subhamoy Das, Mahesh K. Goenka
    Indian Journal of Gastroenterology.2024;[Epub]     CrossRef
  • Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia
    Alaullah Sheikh, Brunda Tumala, Tim J. Vickers, John C. Martin, Bruce A. Rosa, Subrata Sabui, Supratim Basu, Rita D. Simoes, Makedonka Mitreva, Chad Storer, Erik Tyksen, Richard D. Head, Wandy Beatty, Hamid M. Said, James M. Fleckenstein
    Nature Communications.2022;[Epub]     CrossRef
  • Acute Bacterial Gastroenteritis
    James M. Fleckenstein, F. Matthew Kuhlmann, Alaullah Sheikh
    Gastroenterology Clinics of North America.2021; 50(2): 283.     CrossRef
  • Clinical, endoscopic, and histological differentiation between celiac disease and tropical sprue: A systematic review
    Pragya Sharma, Vandana Baloda, Gaurav PS Gahlot, Alka Singh, Ritu Mehta, Sreenivas Vishnubathla, Kulwant Kapoor, Vineet Ahuja, Siddhartha Datta Gupta, Govind K Makharia, Prasenjit Das
    Journal of Gastroenterology and Hepatology.2019; 34(1): 74.     CrossRef
  • What makes non-cirrhotic portal hypertension a common disease in India? Analysis for environmental factors
    Ashish Goel, Banumathi Ramakrishna, Uday Zachariah, K.G. Sajith, Deepak K. Burad, Thomas A. Kodiatte, Shyamkumar N. Keshava, K.A. Balasubramanian, Elwyn Elias, C.E. Eapen
    Indian Journal of Medical Research.2019; 149(4): 468.     CrossRef
  • Nutritional Approach in Tropical Sprue Patients
    Stefanie Knebusch Toriello
    Current Tropical Medicine Reports.2018; 5(3): 211.     CrossRef
  • 11,240 View
  • 114 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
The role of capsule endoscopy in etiological diagnosis and management of obscure gastrointestinal bleeding
Vikas Pandey, Meghraj Ingle, Nilesh Pandav, Pathik Parikh, Jignesh Patel, Aniruddha Phadke, Prabha Sawant
Intest Res 2016;14(1):69-74.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.69
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

To investigate the various etiologies, yields, and effects of capsule endoscopy (CE) on management and complications, along with follow up of patients with obscure gastrointestinal (GI) bleeding.

Methods

The study group of patients included those having obscure, overt, or occult GI bleeding. The findings were categorized as (A) obvious/definitive, (B) equivocal, or (C) negative. Any significant alteration in patient management post CE in the form of drug or surgical intervention was noted.

Results

Total patients included in the study were 68 (48 males and 20 females). The ratio of male:female was 2.4:1. The age ranged between 16 years to 77 years. Mean age for males was 62±14 years, for females 58±16 years. The total yield of CE with definitive lesions was in 44/68 (65.0%) of patients. In descending order (A) angiodysplasia 16/68 (23.53%), (B) Crohn's disease 10/68 (14.70%), (C) non-steroidal anti-inflammatory drug enteropathy 8/68 (11.76%), (D) small bowel ulcers 4/68 (5.88%), (E) jejunal and ileal polyps 2/68 (2.94%), (F) intestinal lymphangiectasis 2/68 (2.94%), and (G) ileal hemangiomas 2/68 (2.94%) were followed. Equivocal findings 12/68 (17.65%) and negative study 12/68 (17.65%) was found. Complications in the form of capsule retention in the distal ileum were noted in 2/68 (2.94%) subjects. Statistically, there was a higher probability of finding the etiology if the CE was done during an episode of bleeding.

Conclusions

CE plays an important role in diagnosing etiologies of obscure GI bleeding. Its role in influencing the management outcome is vital.

Citations

Citations to this article as recorded by  
  • Capsule endoscopy for obscure gastrointestinal bleed in the tropics: A single-center experience on 350 patients
    Uday C. Ghoshal, Piyush Mishra, Akash Mathur, Sai Prathap Reddy, Bushra Fatima, Asha Misra
    Indian Journal of Gastroenterology.2024; 43(5): 1045.     CrossRef
  • Capsule endoscopy for small bowel bleed: Current update
    Uday C. Ghoshal, Akash Roy, Mahesh K. Goenka
    Indian Journal of Gastroenterology.2024; 43(5): 896.     CrossRef
  • An intelligent intestinal bleeding diagnosis and treatment capsule system based on color recognition
    Panpan Qiao, Luo Yu, Hongying Liu, Xueping Yan, Xitian Pi
    Biomedical Microdevices.2023;[Epub]     CrossRef
  • Systematic review and meta‐analysis of the diagnostic and therapeutic yield of small bowel endoscopy in patients with overt small bowel bleeding
    Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Kazuhiro Furukawa, Hiroki Kawashima, Takashi Honda, Masatoshi Ishigami, Mitsuhiro Fujishiro
    Digestive Endoscopy.2021; 33(1): 66.     CrossRef
  • Comparison in the Diagnostic Yield between “Pillcam SB3” Capsule Endoscopy and “OMOM Smart Capsule 2” in Small Bowel Bleeding: A Randomized Head-to-Head Study
    Gerardo Blanco-Velasco, Raúl Antonio Zamarripa-Mottú, Omar Michel Solórzano-Pineda, Miguel Mascarenhas-Saraiva, Juan Manuel Blancas-Valencia, Oscar Victor Hernández-Mondragón
    Digestive Diseases.2021; 39(3): 211.     CrossRef
  • Heterotopia de mucosa gástrica en intestino delgado, hallazgo en videocápsula endoscópica. Reporte de caso
    Santiago Castaño, Natalia Calvache, Mauricio Sepúlveda
    Revista Colombiana de Gastroenterología.2019; 34(3): 314.     CrossRef
  • Meta-analysis shows similar re-bleeding rates among Western and Eastern populations after index video capsule endoscopy
    Georgios Tziatzios, Paraskevas Gkolfakis, Cesare Hassan, Ervin Toth, Angelo Zullo, Anastasios Koulaouzidis, George D. Dimitriadis, Konstantinos Triantafyllou
    Digestive and Liver Disease.2018; 50(3): 226.     CrossRef
  • Lanreotide in the management of small bowel angioectasias: seven-year data from a tertiary centre
    S. Chetcuti Zammit, D. S. Sanders, R. Sidhu
    Scandinavian Journal of Gastroenterology.2017; : 1.     CrossRef
  • Role of capsule endoscopy in suspected or established Crohn's disease in real practice
    Hyun Joo Jang
    Intestinal Research.2017; 15(4): 431.     CrossRef
  • The Role of Dynamic Contrast-enhanced Multidetector-row Computed Tomography in Diagnosis of Obscure Gastrointestinal Bleeding
    Jee Hyun Kim, Jong Pil Im
    The Korean Journal of Gastroenterology.2016; 67(4): 165.     CrossRef
  • 6,476 View
  • 61 Download
  • 10 Web of Science
  • 10 Crossref
Close layer
Gastric lesions in patients with Crohn's disease in Korea: a multicenter study
Hoonsub So, Byong Duk Ye, Young Soo Park, Jihun Kim, Joo Sung Kim, Won Moon, Kang-Moon Lee, You Sun Kim, Bora Keum, Seong-Eun Kim, Kyeong Ok Kim, Eun Soo Kim, Chang Kyun Lee, Sung Pil Hong, Jong Pil Im, Ja Seol Koo, Chang Hwan Choi, Jeong Eun Shin, Bo In Lee, Kyu Chan Huh, Young-Ho Kim, Hyun-Soo Kim, Young Sook Park, Dong Soo Han
Intest Res 2016;14(1):60-68.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.60
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Gastric pathology and Helicobacter pylori (H. pylori) infection among Asian patients with Crohn's disease (CD) are still unclear. We evaluated gastric histologic features and frequency of H. pylori infection in Korean patients with CD.

Methods

Among 492 patients with CD receiving upper gastrointestinal (GI) endoscopic evaluation in 19 Korean hospitals, we evaluated the endoscopic findings and gastric histopathologic features of 47 patients for our study. Histopathologic classification was performed using gastric biopsy tissues, and H. pylori infection was determined using the rapid urease test and histology.

Results

There were 36 men (76.6%), and the median age of patients at the time of upper GI endoscopy was 23.8 years (range, 14.2–60.5). For CD phenotype, ileocolonic disease was observed in 38 patients (80.9%), and non-stricturing, non-penetrating disease in 31 patients (66.0%). Twenty-eight patients (59.6%) complained of upper GI symptoms. Erosive gastritis was the most common gross gastric feature (66.0%). Histopathologically, H. pylori-negative chronic active gastritis (38.3%) was the most frequent finding. H. pylori testing was positive in 11 patients (23.4%), and gastric noncaseating granulomata were detected in 4 patients (8.5%). Gastric noncaseating granuloma showed a statistically significant association with perianal abscess/fistula (P=0.0496).

Conclusions

H. pylori-negative chronic active gastritis appears to be frequent among Korean patients with CD. The frequency of H. pylori infection was comparable with previous studies. An association with perianal complications suggests a prognostic value for gastric noncaseating granuloma in patients with CD.

Citations

Citations to this article as recorded by  
  • Endoscopic findings in the upper gastrointestinal tract in patients with Crohn’s disease are common, highly specific, and associated with chronic gastritis
    Katarzyna Graca-Pakulska, Wojciech Błogowski, Iwona Zawada, Anna Deskur, Krzysztof Dąbkowski, Elżbieta Urasińska, Teresa Starzyńska
    Scientific Reports.2023;[Epub]     CrossRef
  • Detection Rates of Non-Cavitary Epithelioid Cell Granuloma by Gastrointestinal Biopsy in Patients with Treatment-Naïve Crohn’s Disease
    Katsuya Endo, Yoko Kawakami, Yuki Yoshino, Shiho Kondo, Daisuke Fukushi, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Kazuhiro Murakami, Kennichi Satoh
    Inflammatory Intestinal Diseases.2023; 8(3): 105.     CrossRef
  • Beyond Helicobacter: dealing with other variants of gastritis—an algorithmic approach
    Hala El‐Zimaity, Robert H Riddell
    Histopathology.2021; 78(1): 48.     CrossRef
  • Endoscopic and Histopathological Findings of the Esophagus, Stomach, and Duodenum in Patients with Crohn’s Disease from a Reference Center in Bahia, Brazil
    Andrea Maia Pimentel, Luiz Antônio Rodrigues de Freitas, Rita de Cássia Reis Cruz, Isaac Neri de Novais Silva, Laíla Damasceno Andrade, Paola Nascimento Marques, Júlia Cordeiro Braga, Flora Maria Lorenzo Fortes, Katia Rejane Marques Brito, Jaciane Araújo
    Clinics and Practice.2021; 11(2): 374.     CrossRef
  • The gastric microbiota in patients with Crohn’s disease; a preliminary study
    Jerzy Ostrowski, Maria Kulecka, Iwona Zawada, Natalia Żeber-Lubecka, Agnieszka Paziewska, Katarzyna Graca-Pakulska, Krzysztof Dąbkowski, Karolina Skubisz, Patrycja Cybula, Filip Ambrożkiewicz, Elżbieta Urasińska, Michał Mikula, Teresa Starzyńska
    Scientific Reports.2021;[Epub]     CrossRef
  • Associations between the Presence of Granulomata and Disease Phenotype and Outcomes in Children Diagnosed with Crohn’s Disease
    Laura Appleton, Euan Watt, Fiona Jagger, Richard Hansen, Richard B. Gearry, Andrew S. Day
    Gastrointestinal Disorders.2020; 2(2): 164.     CrossRef
  • Ovarian Crohn’s Disease: A Case Report and Review of the Literature
    Hamza Mohammed, Rana Bokhary, Mohammed Nassif, Mahmoud Mosli, Haruhiko Sugimura
    Case Reports in Gastrointestinal Medicine.2020; 2020: 1.     CrossRef
  • Crohn’s disease of esophagus, stomach and duodenum
    Andréa Maia Pimentel, Raquel Rocha, Genoile Oliveira Santana
    World Journal of Gastrointestinal Pharmacology and Therapeutics.2019; 10(2): 35.     CrossRef
  • Prognostic significance of granulomas in children with Crohn’s disease
    Benjamin Rothschild, Firas Rinawi, Yonatan Herman, Osnat Nir, Raanan Shamir, Amit Assa
    Scandinavian Journal of Gastroenterology.2017; 52(6-7): 716.     CrossRef
  • Endoscopic Bamboo Joint-like Appearance of the Stomach in Crohn's Disease
    Kwang Il Seo, Won Moon
    The Korean Journal of Gastroenterology.2017; 69(2): 151.     CrossRef
  • Characteristics of Upper Gastrointestinal Tract Involvement in Korean Pediatric Crohn's Disease: A Multicenter Study
    Ji Hyoung Park, Hye Na Nam, Ji-Hyuk Lee, Jeana Hong, Dae Yong Yi, Eell Ryoo, In Sang Jeon, Hann Tchah
    Pediatric Gastroenterology, Hepatology & Nutrition.2017; 20(4): 227.     CrossRef
  • Increased duodenal expression of miR-146a and -155 in pediatric Crohn’s disease
    Dániel Szűcs, Nóra Judit Béres, Réka Rokonay, Kriszta Boros, Katalin Borka, Zoltán Kiss, András Arató, Attila J Szabó, Ádám Vannay, Erna Sziksz, Csaba Bereczki, Gábor Veres
    World Journal of Gastroenterology.2016; 22(26): 6027.     CrossRef
  • 7,727 View
  • 70 Download
  • 10 Web of Science
  • 12 Crossref
Close layer
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi
Intest Res 2016;14(1):50-59.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.50
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

The therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients. This study aimed to provide new insight for dose optimization using two doses of pH-dependent release mesalamine for induction of remission of moderately active ulcerative colitis (UC).

Methods

In a multicenter, double-blind, randomized study, 110 patients with moderately active UC were assigned to two groups after treatment with a constant dose of mesalamine. Fifty-five patients were treated with a pH-dependent release formulation of 3.6 or 4.8 g/day for 8 weeks. The primary endpoint was a decrease in the UC disease activity index (UCDAI) adjusted by covariates.

Results

In the full analysis set (n=110), the mean decrease in UCDAI was 3.1 in the 3.6 g/day group and 3.4 in the 4.8 g/day group (P>0.05). In a subgroup analysis, the effectiveness of the 4.8 g/day dose was greater in particular populations, such as those who had been previously treated with a lower dose of mesalamine and those with more severe disease. The safety was comparable between the two groups.

Conclusions

The results suggest that treatment with pH-dependent release mesalamine at either 3.6 or 4.8 g/day was effective and safe for the induction of remission in patients with moderately active UC. However, the patients receiving mesalamine at 2.4 g/day but in whom the therapeutic effect is not sufficient and having more severe symptoms (UCDAI 9-10), benefit from higher doses of mesalamine compared to others.

Citations

Citations to this article as recorded by  
  • Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
    Ajit Sood, Vineet Ahuja, Vandana Midha, Saroj Kant Sinha, C. Ganesh Pai, Saurabh Kedia, Varun Mehta, Sawan Bopanna, Philip Abraham, Rupa Banerjee, Shobna Bhatia, Karmabir Chakravartty, Sunil Dadhich, Devendra Desai, Manisha Dwivedi, Bhabhadev Goswami, Kir
    Intestinal Research.2020; 18(4): 355.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
    Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
    Intestinal Research.2017; 15(3): 368.     CrossRef
  • Remission endpoints in ulcerative colitis: A systematic review
    Maki Jitsumura, Rory Frederick Kokelaar, Dean Anthony Harris
    World Journal of Meta-Analysis.2017; 5(4): 85.     CrossRef
  • Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease
    Celestine Wong, Philip Harris, Lynnette Ferguson
    International Journal of Molecular Sciences.2016; 17(6): 919.     CrossRef
  • What is the real-life maintenance mesalazine dose in ulcerative colitis?
    Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferre, Daniel Bonillo, Lara Aguilera, Antonio López-Sanromán, Fernando Bermejo
    Revista Española de Enfermedades Digestivas.2016;[Epub]     CrossRef
  • 6,000 View
  • 66 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease
Dae Sung Lee, Ki Bae Bang, Ji Yeon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Young Choi, Dong Il Park
Intest Res 2016;14(1):43-49.   Published online January 26, 2016
DOI: https://doi.org/10.5217/ir.2016.14.1.43
AbstractAbstract PDFPubReaderePub
<b>Background/Aims</b><br/>

Quality of life is closely related to anemia in patients with inflammatory bowel disease (IBD). Several studies have reported on anemia in patients with IBD in Western countries. This study investigated the prevalence and clinical characteristics of anemia in Korean patients with IBD.

Methods

We reviewed the medical records of 92 patients with ulcerative colitis (UC) and 76 patients with Crohn's disease (CD) who were followed regularly at a single tertiary medical center in Korea between January 2003 and December 2012. Hemoglobin (Hb) thresholds used to define anemia were <13.0 g/dL in men and <12.0 g/dL in women according to the World Health Organization criteria. We chose the lowest Hb level in each year as a representative value because Hb levels changed at each examination and anemia was associated with disease deterioration. The relationship between clinical variables and lowest Hb level was assessed.

Results

The prevalence of anemia was 36.3% in patients with UC and 41.6% in patients with CD. Anemia in patients with CD was associated with hospital admission, 5-aminosalicylate (5-ASA) and infliximab treatment in men. Anemia in patients with UC was associated with hospital admission, oral steroid use, thiopurine and infliximab treatment in men.

Conclusions

The prevalence of anemia in Korean patients with IBD was comparable to that of patients in Western countries. Anemia was associated with male patients with CD who were admitted to the hospital and received medications including 5-ASA and infliximab, and men with UC who were admitted to the hospital and received medications including oral steroids, thiopurine and infliximab.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and north-south differences of inflammatory bowel disease in China: A cross-sectional study and meta-analysis
    Qi Liang, Bo Qu, Chunye Li, Yue Hu, Chunyi Yang, Tingting Yang, Yuzhu Di, Hui Li
    Frigid Zone Medicine.2024; 4(1): 23.     CrossRef
  • Clinical and Laboratory Characteristics of Anaemia in Hospitalized Patients with Inflammatory Bowel Disease
    Małgorzata Woźniak, Anna Borkowska, Marta Jastrzębska, Marcin Sochal, Ewa Małecka-Wojciesko, Renata Talar-Wojnarowska
    Journal of Clinical Medicine.2023; 12(7): 2447.     CrossRef
  • Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study
    Natália Souza Nunes Siqueira, Livia Bitencourt Pascoal, Bruno Lima Rodrigues, Marina Moreira de Castro, Alan Sidnei Corrêa Martins, Dante Orsetti Silva Araújo, Luis Eduardo Miani Gomes, Michel Gardere Camargo, Maria de Lourdes Setsuko Ayrizono, Raquel Fra
    World Journal of Clinical Cases.2023; 11(12): 2740.     CrossRef
  • ANEMIA AND IRON DEFICIENCY IN INFLAMMATORY BOWEL DISEASE PATIENTS IN A REFERRAL CENTER IN BRAZIL: PREVALENCE AND RISK FACTORS
    Rogério Serafim PARRA, Marley Ribeiro FEITOSA, Sandro da Costa FERREIRA, José Joaquim Ribeiro da ROCHA, Luiz Ernesto de Almeida TRONCON, Omar FÉRES
    Arquivos de Gastroenterologia.2020; 57(3): 272.     CrossRef
  • Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease
    Göksel Bengi, Hatice Keyvan, Seda Bayrak Durmaz, Hale Akpınar
    World Journal of Gastroenterology.2018; 24(36): 4186.     CrossRef
  • Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease
    Seong Jae Yeo, Hyun Seok Lee, Byung Ik Jang, Eun Soo Kim, Seong Woo Jeon, Sung Kook Kim, Kyeong Ok Kim, Yoo Jin Lee, Hyun Jik Lee, Kyung Sik Park, Yun Jin Jung, Eun Young Kim, Chang Heon Yang
    Intestinal Research.2018; 16(3): 400.     CrossRef
  • Should asymptomatic young men with iron deficiency anemia necessarily undergo endoscopy?
    Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
    The Korean Journal of Internal Medicine.2018; 33(6): 1084.     CrossRef
  • Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients
    Alfredo J. Lucendo, Ángel Arias, Óscar Roncero, Daniel Hervías, Cristina Verdejo, Carmen Naveas-Polo, Abdelmouneim Bouhmidi, Rufo Lorente, Luis Miguel Alcázar, Irina Salueña, Julio A. García-Quiñones, María Jesús Carrillo-Ramos
    Digestive and Liver Disease.2017; 49(4): 405.     CrossRef
  • 5,913 View
  • 66 Download
  • 8 Web of Science
  • 8 Crossref
Close layer

Intest Res : Intestinal Research
Close layer
TOP